



Inhibiting the Ins and Outs of HIV Replication: Cell-Intrinsic Antiretroviral Restrictions at the Plasma Membrane

Toshana L. Foster*, Suzanne Pickering* and Stuart J. D. Neil*

Department of Infectious Disease, School of Immunology and Microbial Sciences, King's College London, London, United Kingdom

OPEN ACCESS

Edited by:

Aurelio Cafaro,
Istituto Superiore di Sanità, Italy

Reviewed by:

Elisa Vicenzi,
San Raffaele Hospital (IRCCS), Italy
Andrew McGuire,
Fred Hutchinson Cancer Research
Center, United States
Eric Hunter,
Emory University, United States
Levon Abrahamyan,
Université de Montréal, Canada

*Correspondence:

Toshana L. Foster
toshana.foster@kcl.ac.uk;
Suzanne Pickering
suzanne.pickering@kcl.ac.uk;
Stuart J. D. Neil
stuart.neil@kcl.ac.uk

Specialty section:

This article was submitted to
HIV and AIDS,
a section of the journal
Frontiers in Immunology

Received: 15 September 2017

Accepted: 07 December 2017

Published: 04 January 2018

Citation:

Foster TL, Pickering S and Neil SJD
(2018) Inhibiting the Ins and Outs of
HIV Replication: Cell-Intrinsic
Antiretroviral Restrictions at the
Plasma Membrane.
Front. Immunol. 8:1853.
doi: 10.3389/fimmu.2017.01853

Like all viruses, human immunodeficiency viruses (HIVs) and their primate lentivirus relatives must enter cells in order to replicate and, once produced, new virions need to exit to spread to new targets. These processes require the virus to cross the plasma membrane of the cell twice: once via fusion mediated by the envelope glycoprotein to deliver the viral core into the cytosol; and secondly by ESCRT-mediated scission of budding virions during release. This physical barrier thus presents a perfect location for host antiviral restrictions that target enveloped viruses in general. In this review we will examine the current understanding of innate host antiviral defences that inhibit these essential replicative steps of primate lentiviruses associated with the plasma membrane, the mechanism by which these viruses have adapted to evade such defences, and the role that this virus/host battleground plays in the transmission and pathogenesis of HIV/AIDS.

Keywords: human immunodeficiency virus, type I interferons, antiviral restriction, plasma membrane, tetherin/BST-2, serine incorporator, interferon-induced transmembrane

INTRODUCTION

A key feature of eukaryotic cells is the plasma membrane (PM), the single lipid bilayer that delimits the cytoplasm from the extracellular milieu (1). As well as acting as the physical boundary of the cell, the PM acts as a platform which plays a role in almost every cellular process, from regulating transport of small molecules and proteins in out of the cell, to cell mobility, and the response to its environment. As such, any infectious agent that seeks to gain access to the cell's cytosol must breach the PM or the limiting membranes of intracellular compartments. In the case of enveloped viruses, this entails an entry step in which viral envelope glycoproteins engage specific cellular receptors on the PM or undergo low pH-induced conformational changes upon endocytic uptake (2, 3). As a result of either of these processes, mechanisms intrinsic to the glycoproteins themselves mediate fusion between the viral and host cell membranes, allowing the viral genetic material to enter the cell and initiate the replication cycle. For lentiviruses, the replication cycle culminates in newly synthesized RNA genomes and viral structural proteins being targeted to the inner leaflet of the PM (4). With the aid of a multitude of cellular factors, new virus particles assemble and bud into the extracellular space, acquiring their lipid envelope from the host cell. Budding ends in a scission event that separates the new virion from the cell, allowing it to be released and infect new targets.

These unavoidable processes are common to all enveloped viruses. Moreover, the lipid envelope is the one component of the virus particle that is not encoded by the virus itself. It is perhaps unsurprising that the mammalian host has evolved multiple antiviral mechanisms whose role is to inhibit viral replicative processes that are associated with entry and exit (5–8), necessitating either the evolution of directly encoded countermeasures by the virus, or other mechanisms of resistance or avoidance. Furthermore, these mechanisms are often (but not always) regulated by type 1 interferons (IFN-I) and pattern recognition responses, linking these factors to the wider antiviral immune response.

OVERVIEW OF LENTIVIRAL ENTRY AND EXIT

The mediator of the entry of HIV-1 and its related viruses is the trimeric envelope spike [reviewed in Ref. (9)]. For HIV-1, this is comprised of three precursor Env proteins, gp160, that are proteolytically cleaved into a surface subunit, gp120, and a transmembrane subunit gp41. gp120 harbours the receptor binding components of the envelope spike whereas gp41 encodes the fusion machinery itself, buried within the trimer. gp120 consists of a series of conserved domains interspersed with variable loops and is heavily glycosylated on the outer faces of the trimer (10). There are surprisingly few spikes on the surface of the virion, with estimates of about 10–20 (11). Super-resolution microscopy imaging of HIV-1 particles has shown that these spikes cluster, which appears to be important for fusogenicity (12).

The Env trimer is a metastable structure, poised to mediate viral entry upon interaction with its receptor(s) (9). When gp120 binds to its cognate receptor, CD4 (13–15), on the target T cell or macrophage, structural rearrangements “open” the envelope to reveal a coreceptor binding site (16–18). This interacts with either CCR5 (19–21) or CXCR4 (22), and occasionally additional CC chemokine receptors. Upon coreceptor binding, further conformational changes expose the hydrophobic fusion peptide of gp41, which rapidly inserts in the target membrane. The extended conformation of the gp41 trimer collapses back to form a six-helix bundle common to diverse type 1 enveloped virus fusion proteins (9). This pulls the viral and cellular membranes together, and is sufficient to locally destabilise the membranes, allowing lipid mixing, fusion, and the release of the viral core into the cell (9).

The use of CCR5 appears to be essential for sexual transmission of HIV-1. Viruses that use CCR5 alone (R5), or more rarely CCR5 and CXCR4 [R5/X4 or dual tropic (23)], predominate in early infection (24, 25). Individuals homozygous for a 32 base pair deletion in CCR5 that disrupts its expression are largely HIV-1 resistant (26, 27). X4-using viruses tend to arise later in infection in some, but not all, individuals, and are associated with more rapid progression to AIDS. Whilst they can be transmitted by intravenous drug-use/transfusion, it is not clear why X4 viruses are almost never transmitted sexually given that target CD4+ T cells in the mucosa express CXCR4 (25). The selective pressures that produce the so-called coreceptor switch are not well understood, but it is associated with changes in the V3 loop of gp120 and perhaps arises through escape from

certain classes of neutralizing antibody (28). Coreceptor usage in part determines the cellular tropism of the virus; R5 viruses infect predominantly subsets of antigen-experienced CD4+ T cells, whereas X4 usage expands this tropism to naïve cells (9). Macrophage-tropic viruses are almost exclusively R5 users, but importantly macrophage tropism is determined by changes in gp120 that allow it to use much lower cell surface concentrations of CD4 (29, 30). Thus most R5 isolates, including those transmitted between individuals (the so called transmitted-founder (TF) viruses) can only infect T cells (31). Quite why the majority of X4 viruses cannot infect macrophages which express abundant CXCR4 is not known (32).

Where entry occurs in the cell has been of some controversy. The pH-independence of HIV-1 entry would suggest that it occurs at the cell surface (2, 33). This was reinforced by early studies showing that endocytosis of CD4 was not necessary for productive viral entry (34). However, more recent studies have shown that HIV-1 entry is sensitive to certain endocytosis inhibitors, particularly those targeting the GTPase dynamin-2 (35). These effects may be cell-type dependent, as entry appears to be predominantly cell surface in T cell lines (36). Furthermore dynamin-2 may play a role in fusion, independent of its activity in endocytosis (37). Much further work, particularly with clinically relevant isolates, is required to fully rationalize many of these observations. However, the ability of certain membrane associated antiviral factors to differentially restrict HIV-1 entry dependent on their own subcellular localization may allow further insight into these issues.

The next encounter of HIV-1 with the limiting membrane of the cell is viral assembly [reviewed in Ref. (4, 38)]. For lentiviruses, this occurs exclusively at the plasma membrane. Small amounts of Gag and Gag-Pol polyproteins are targeted to the inner leaflet of the PM, bringing with them two copies of the viral genomic RNA. This allows more Gag/Gag-Pol to nucleate around them, and in doing so form a budding virion. Small peptide motifs in the p6 portion of Gag (termed late domains) interact with several members of the ESCRT pathway, a multi component protein machinery that resolves membrane-bound entities budding away from the cell's cytoplasm. The recruitment of the core ESCRT-I subunit TSG101 is the major event in initiating HIV-1 release, although other associated factors can also directly interact with Gag. This then leads to the recruitment of charged multivesicular protein (CHMP) subunits of ESCRT-III. The polymerization of these ESCRT-III subunits into filaments around the inside of the stem of the budding virions and their subsequent depolymerization by the AAA-ATPase VPS4, leads to the contraction of the neck of the bud and the final scission of the virus from the cell. During the budding process, mature Env trimers are recruited into the assembling virion, as well as a number of other host membrane proteins; some beneficial, others, as described below, less so. Co-incident with the latter stages of budding, dimerization of the protease component of the Gag-Pol polyprotein, driven by interactions between reverse transcriptase moieties, activates its catalytic activity. This then leads to the sequential processing of the Gag and Gag-Pol to generate the mature structural and enzymatic components of the infectious virion.

TYPE 1 INTERFERONS AND THE RESTRICTION OF HIV-1 REPLICATION

A burst of systemic inflammatory cytokines driven by type 1 interferons (IFN-I) is one of the earliest host responses detectable in HIV-1 infected individuals (39). Despite the virus being adept at avoiding host pattern recognition receptors in infected cells (see review by Sumner et al. in this issue), the consequence of the rapid increase in viral replication is that systemic IFN-I levels are detectable as early as 7 days after infection. Both alpha and beta interferons activate the same receptor, IFNAR1/2, expressed on the majority of somatic cells, and via the Jak/STAT pathway induce the transcription of hundreds of so-called interferon-stimulated genes (ISGs), many of which, like IFN-I themselves, are also activated directly by pattern recognition responses (40). In addition to the activation of systemic innate and adaptive immunity, a number of these ISGs have direct antiviral activity against the replicative stages of diverse mammalian viruses (7). These antiviral factors, sometimes called restriction factors, often target common pathways or structures that are essential for viral replication, and which cannot be simply mutated around. In the case of lentiviruses, several restriction factors have been identified that are targets of virally encoded accessory proteins (41), for example tetherin and Vpu described below. The evolutionary arms race between these countermeasures and species-specific orthologues of these restriction factors has shaped the adaptation of these viruses to new primate hosts, ultimately allowing chimpanzee and sooty mangabey simian immunodeficiency viruses to cross into humans to become HIV-1 and HIV-2 respectively (42). However, ectopic expression of a number of ISGs have a direct antiviral activity against HIV-1 with no obvious virally-encoded countermeasure (43). HIV-1 replication can be inhibited in primary CD4+ T cells and macrophages in culture by IFN-I treatment, indicating some of these ISGs may play a physiological role in early infection (43, 44). Furthermore, treating HIV-infected patients with pegylated-IFN leads to a transient reduction in viral loads (45). In macaques, although initial mucosal inflammatory activation may inhibit local ISG activation (46), early viremic control of SIVmac infection is dependent on systemic IFN-I responses (47). But perhaps the most powerful evidence of the importance of directly antiviral ISGs in HIV-1 pathogenesis comes from the observation that viruses that represent the most likely founder of an individual's infection, called transmitted/founder (TF) viruses, display a considerably higher resistance to the effects of IFN-I in their replication in primary CD4+ T cells than viruses isolated during the chronic phase (31, 48). While initially controversial in a replication study in subtype C infections using blood-derived viral sequences (49), these observations have been extended and now show that the TF virus sequence in a recipient partner is the most IFN-I resistant amongst the viral quasi-species that existed in the donor partners' genital secretions at the time of transmission in both clades B and C, thus indicating IFN-I resistance is a key attribute for transmission fitness (50). Curiously, as infection progresses, IFN-I resistance in circulating virus wanes (48). There are multiple molecular determinants of this difference in IFN sensitivity between TF and chronic viruses from the same the donor, suggesting a number of

ISGs are involved (50). In the sections below, we will discuss host restriction factors and antiviral ISGs that target the entry and exit pathways of the virus.

THE INTERFERON-INDUCED TRANSMEMBRANE (IFITM) PROTEIN FAMILY

The interferon-induced transmembrane (IFITM) proteins are a family of antiviral factors that restrict the fusion of a number of pathogenic enveloped viruses with their target cells, including influenza A virus (IAV), Dengue virus (DENV), hepatitis C virus (HCV), Ebola virus (EBOV) and HIV (51–53). They are predominantly located at the PM and on endosomal membranes, the portals of entry for most viruses (54, 55). Recent studies have sought to identify the mechanisms of their antiviral restriction activities that may explain this broad spectrum activity, which primarily target the entry stages of the viral lifecycle.

Five members of the gene family have been identified in humans, *ifitm 1, 2, 3, 5 and 10*, all clustered on chromosome 11 (56, 57). Unlike *ifitms 1, 2 and 3*, *ifitm5* is not induced by type 1 or type 2 interferons but has been proposed to be involved in bone mineralization. A function for *ifitm10* has not been identified. In the mouse genome, the orthologues of the human *ifitm* genes are located on chromosome 7, with the pseudogene *ifitm4*, also not functional in humans, located in close proximity to *ifitm 1, 2 and 5*. Analogous genes have been identified in other mammals and in the avian species, where the IFITM proteins serve to inhibit influenza viruses.

IFITM Structure and Localisation

IFITMs are members of a larger superfamily of proteins found in both eukaryotes and prokaryotes, known collectively as dispanins (58). Structurally, the IFITMs each contain two hydrophobic domains that are separated by a short conserved intracellular loop (CIL) containing a CD225-like domain; speculation has however surrounded the topological conformation of the domains within the membrane. The current biochemical and cell biology evidence suggest that the IFITMs adopt a topology in which the N-terminus and CIL reside in the cytoplasm, with the first hydrophobic domain existing as an intra-membrane domain whilst the second hydrophobic domain spans the membrane such that the C-terminus resides in the extracellular space (Figure 1A) (54, 55, 59). The CIL domain also contains palmitoylation sites that likely stabilize this conformation (60–62). The intramembrane helices of the first hydrophobic domain are postulated to influence the curvature of the membrane in which the IFITM resides thus impacting the restriction activity (59). Evidence of self-association and intramolecular interactions between the IFITM proteins, via residues within the first transmembrane domain, has been reported, suggesting that higher order multimers may have functional implications (63).

Mammalian IFITMs are highly homologous at the amino acid level, and in particular IFITMs 2 and 3 in primates display highly complex positive selection signatures (64) suggesting that they are continually adapting to target pathogenic viruses (65). Such




FIGURE 1 | Schematic representation of IFITMs, SERINC 3/5 and tetherin within a model membrane. **(A)** A model of the IFITM protein, which adopts a type II transmembrane protein topology in the membrane. The N-terminal domain lies within the cytoplasm and connects to two short intramembrane α -helices. IFITMs 2 and 3 possess a longer N-terminal domain that contains important trafficking motifs that determine protein localisation. The conserved intracellular loop (CIL) contains sites of palmitoylation that likely stabilise the conformation of the C-terminal transmembrane α -helix which spans the membrane, thus positioning the C-terminal domain within the extracellular space. **(B)** Very little information about the structures of SERINC proteins is currently known. SERINC3 and 5 are thought to possess between 10 and 12 transmembrane helices such that the N- and C-termini reside within the extracellular space. **(C)** Tetherin exists as a dimer anchored to the membrane via an N-terminal transmembrane domain and a C-terminal GPI anchor. The extracellular portion of tetherin is comprised of a coiled coil. The N-terminal cytoplasmic tail contains a dual tyrosine motif that plays a role in both steady-state cycling of the protein and signal transduction following virus retention. Amino acid sequences of human and chimpanzee cytoplasmic tails are shown for comparison, highlighting the deletion of the DIWKK motif. The short isoform of human tetherin lacks the first 12 amino acids of the cytoplasmic tail.

selection raises the notion that they may be under pressure to provide a continuous barrier across the entry portals into the cell. Consistent with this, human IFITMs localize to distinct but overlapping cellular membranes (54). While IFITM1 appears to be mainly associated with the PM, the longer N-terminal cytoplasmic tail of IFITMs 2 and 3 contain a Yxx Φ endocytic motif that permits their localization to early/recycling (IFITM3) and late (IFITM2) endosomal compartments (66, 67). This sorting signal overlaps with an endosomal degradation motif (PPxY) that regulates their turnover (**Figure 1A**) (68). Importantly, therefore, both endosomal IFITMs dynamically traffic via the cell surface to reach their major sites of localization. This localization is a key determinant of the antiviral spectrum which a given IFITM restricts because the mechanism of entry of different viruses (receptor requirements, pH thresholds of fusion etc.) define their sites of access to the cell. For example, mutation of the endocytic motif in IFITM3 such that it redistributes to the cell surface abolishes its antiviral activity against IAV (67). This has major implications for the discussion of their effects on HIV below.

Mechanism of IFITM Restriction

IFITMs appear to block the physical fusion of enveloped viruses with their target membranes, however the mechanism of action is not clear. It is widely postulated from the work of Brass, Liu

and others particularly on IAV, that the mechanism of action is through modulation of the host cell membrane fluidity to block viral fusion (69–73). These “tough-membrane” models suggest a number of possible mechanisms: (1) Adjacent IFITM molecules may interact via their intramembrane domains thereby decreasing the fluidity of the host membrane and limiting the lateral movement of host entry receptors and formation of productive receptor complexes. (2) These intramolecular interactions may prevent the effective viral envelope clustering that is required particularly for IAV fusion and (3) the IFITM multiplexes could also form a “meshwork” within the outer leaflet of the membrane that not only decreases fluidity and imposes rigidity but induces an outward membrane curvature that opposes the forces exerted by the viral fusion machinery. These general mechanisms may account for the diversity of viruses inhibited, including non-enveloped viruses, such as reoviruses, that do not require fusion, but do need to disrupt the endosomal membrane to enter the cell (74). Such models are also consistent with observations of IAV and Semliki Forest virus (SFV) accumulating in endosomal compartments where the restricting IFITM resides, without affecting the pH-dependent exposure of the viral fusion machinery (70, 71, 75). Studies have demonstrated that IFITM-mediated restrictions of fusion can be overcome by antifungal drugs that target cholesterol metabolism, and oleic acid treatment that is predicted

to reverse the positive membrane curvature exerted by the IFITM (72, 73). Dye-dequenching transfer experiments using labelled IAV virions suggest that hemifusion, the mixing of lipids from the outer leaflets of viral and cellular membranes, still occurs in the presence of the IFITM (70, 72). However, whether this is generalizable to all enveloped virions is not known.

One related mechanism, suggested by Amini-Bavil-Olyaei et al., is that the direct interaction of IFITM3 with vesicle membrane protein associated protein A (VAPA) leads to a disruption of the VAPA-oxysterol binding protein (OSBP) function that acts to regulate intracellular cholesterol homeostasis (69). In the presence of IFITM3, endosomal membranes become cholesterol laden, less fluid and functionally impaired, thus blocking viral entry. However, other studies have failed to replicate the latter observation (70), and the lack of VAPA interaction with IFITM1 or 2 is difficult to reconcile with their antiviral properties. Lastly, a recent study has suggested that a ubiquitous zinc metalloprotease, ZMPSTE24, previously implicated in processing nuclear lamins, is an essential cofactor for IFITMs independent of its catalytic activity (76). As yet, the mechanism for its role is not known.

Restriction of HIV by IFITMs

All three IFITM proteins have been demonstrated to affect HIV-1 entry and replication, albeit to a lesser degree compared to their effects on other viruses. However, there has been some controversy over their potency and mode of action. The initial study from the Liang group, based on T cell lines ectopically expressing individual doxycycline-inducible IFITMs showed that IFITM2 and IFITM3 could block the entry of a model X4-using laboratory strain, but all three IFITMs could block spreading replication, suggesting multiple stages of the HIV-1 replication cycle were sensitive to IFITM restriction (53). While these differential effects on HIV-1 entry and replication were observed in the target cells, two further studies explored the role of IFITMs in HIV-1 producer cells (77, 78). Both groups observed that IFITMs were incorporated into viral particles, making the particles less infectious. They hypothesized that through cell-cell transmission, the virions were able to circumvent the effect of IFITMs in target cells but cell-free virus spread from infected producer cells is limited as the virions produced become increasingly less infectious through IFITM incorporation (**Figure 2A**). While IFITM3 was found to accumulate at sites of viral assembly on the PM, neither study reported a specific interaction with the envelope glycoprotein or an effect on envelope density due to IFITM incorporation. A third study reported that IFITM overexpression caused an infectivity defect to virions not because of their incorporation *per se*, but because they appeared to directly interact with nascent gp160 and block its processing to its mature subunits (79). The major caveat to all these studies is that the majority of the mechanistic data are based on un-physiological overexpression mediated either by transient transfection or drug-induction. Whilst all the studies performed RNAi-mediated depletion of IFITM expression levels (which is challenging because of high homology between the IFITMs) to show that a prototypical HIV-1 isolate replicates better in target cells, that this phenotype is because of the mechanisms proposed is unclear. In particular, the block to gp160 processing has not been reproduced by others under more physiological

IFITM expression levels (65, 80). However, virion incorporation of IFITMs as a mechanism of reducing viral infectivity has been suggested for diverse enveloped viruses (81).

The subcellular site at which HIV-1 enters has been controversial. Recently, we wondered whether IFITM-mediated restriction might shed light on this controversy (80). Using a panel of model cell lines based on the neuroblastoma cell line U87-MG (long used in HIV-1 entry studies because they express no CD4 or endogenous major coreceptors), we expressed individual IFITMs at interferon-induced expression levels alongside CD4 and CXCR4 or CCR5. We found that IFITM restriction of HIV-1 was mediated by all three proteins but that there was a dependence on the viral co-receptor usage (**Figure 2A**). Virions that required the CCR5 co-receptor were more susceptible to inhibition by IFITM1 at the plasma membrane whilst CXCR4-using virions were more sensitive to IFITMs 2 and 3 that are predominantly localised within endosomal compartments. We therefore hypothesized that both properties of the viral envelope and that of the IFITM, in particular its subcellular localisation, dictated this “specificity” of inhibition. We showed that mutation of Y19/Y20 that mislocalises IFITMs 2 and 3 to the plasma membrane, or direct blockade of endocytosis, also modulates the restriction activity of these proteins against HIV-1 virus isolates that differ in their sensitivity to restriction by IFITM1 or IFITMs 2 and 3. HIV-1 envelope glycoproteins that were usually sensitive to restriction by IFITMs 2 and 3 were now insensitive in both one-round entry assays and spreading replication. The observation that this did not impair virion incorporation of the IFITM indicated that the primary mode of restriction was the blocking of viral entry by the IFITM expressed on the target cell membrane. These data implied that the pattern of IFITM-mediated restriction of a given envelope indicated different sites of entry—some viruses may fuse at the PM; others in, or en route to, endosomal compartments (**Figure 2A**). Three independent studies have also linked coreceptor use and IFITM sensitivity [(82, 83) #870] (81). In particular, Huang and colleagues (83) identified a putative splice variant ($\Delta 20$ IFITM2) of IFITM2 that lacks the N-terminal 20 amino acids of the full-length protein. They report higher endogenous expression of this isoform in monocytes and in CD4+ T-cells compared to the full-length protein, with localisation of the variant both at the plasma membrane and in endosomal compartments. They found that several R5-tropic viruses were resistant to inhibition by $\Delta 20$ IFITM2 with the cytoplasmic tail of CCR5, containing the major trafficking and signaling motifs, being a major determinant of this resistance. By contrast a diverse range of X4-tropic viruses were highly susceptible to inhibition. Whilst confirming that coreceptor usage also affected sensitivities to full length IFITM2 and IFITM3-mediated entry restriction, they found this was cell-type dependent, further highlighting the complexities of IFITM-mediated restriction of HIV entry. Interestingly, the authors showed that IFITM2 knockdown in primary dendritic cells led to a 2-fold increase in their permissivity to X4 viruses. Whilst it is unclear if this was a significant gain in replication capacity for myeloid cells, it raises the possibility that X4 viruses might lack macrophage tropism in part through active host restrictions that R5 viruses avoid, something previously suggested by Schmidtmerova et al. 20 years ago (84).




FIGURE 2 | Restriction of HIV-1 entry at the plasma membrane. **(A)** IFITMs. The antiviral restriction activity of the interferon induced transmembrane (IFITM) protein family appears to be linked to the site of viral fusion. The current general mechanism of action proposed, i.e. the physical fusion of the viral and host cell membranes is blocked, accounts for the diversity of viruses that IFITMs restrict. The influence of complex cellular trafficking pathways on this mechanism is yet to be determined. IFITMs 1, 2 and 3 are localised in different membrane compartments; IFITM1 primarily at the plasma membrane and IFITMs 2 and 3 in overlapping intracellular endocytic compartments—the sites of enveloped virus fusion. HIV-1 entry requires the CD4 receptor and co-receptors CCR5 or CXCR4 and it appears that HIV-1 sensitivity to IFITM restriction is influenced both by IFITM localisation and the site of fusion. Fusion that occurs at the plasma membrane is susceptible particularly to an IFITM1 mediated block. IFITMs 2 and 3 appear to restrict any fusion events that bypass the plasma membrane and occur within the intracellular compartments. IFITMs incorporated into viral particles during budding mediate their restriction on the target cell as the virus progeny become increasingly less infectious due to IFITM incorporation. **(B)** SERINC 3 and 5. The transmembrane proteins SERINC3 and SERINC5 are incorporated into budding HIV-1 particles from the membrane of the infected cell. In the absence of the Nef protein, HIV-1 infectivity in the target cell is restricted as delivery of the viral core is reduced due to a block to fusion. Conversely, in the presence of Nef, SERINC3/5 are relocalised from the plasma membrane through dynamin- and clathrin-dependent endocytosis, thus restoring viral infectivity and allowing for successful fusion of the progeny virions that lack SERINC3/5, with the target cell. **(C)** Other lentiviral restrictions at the plasma membrane. The post-entry restriction activity of lentivirus susceptibility factors 2 and 3 (Lv2/3) is dependent on the fusion events at the plasma membrane. Both envelope and capsid are determinants of Lv2 mediated restriction that blocks reverse transcription and nuclear entry. Likewise, RNA-associated early stage antiviral factor (REAF) which has been identified as a potent effector of Lv2, blocks reverse transcription in a similar manner dependent on the route of entry. The Lv3 block is a TRIM5α-independent process that is dependent on envelope interactions with viral entry receptors. The cell specific restriction factor TRIM5α, binds to capsid and forms a lattice leading to premature disassembly of the core. In Langerhans cells, HIV-1 uptake by the C-type lectin Langerin leads to recruitment of TRIM5α and a post-fusion block that occurs prior to integration. Conversely, in other DC subsets, interaction with DC-SIGN, induces a signalling cascade that facilitates reverse transcription and prevents TRIM5α restriction.

The importance of IFITM-Mediated Restriction in Transmission and Acute Infection

Amongst the viruses tested in our study, we showed that envelopes from R5-tropic TF viruses were uniformly resistant to IFITM restriction (80). Intriguingly, matched virus clones representing the majority species from the same individual at 6 months had gained substantial sensitivities to IFITM2 and 3 in particular. Again this was envelope determined, and was lost upon relocalization of the IFITM to the PM, suggesting that changes in Env during those 6 months had affected the route of viral entry, despite no change in coreceptor usage occurring. A major determinant of the IFITM-resistance of the TF virus was the cell surface level of CD4, suggesting that receptor engagement and density were key requirements. Consistent with this idea, selection of X4 HIV-1 resistance to IFITM1 by the Liang group yielded viruses

with lesions in Vpu and changes in the CD4 binding site of Env (85). Such adaptations in culture will lead to a modulation of the envelope structure during assembly (see tetherin section below). The differences in Env between TF and 6 month viruses varied between individuals. It is well known that gp120 and gp41 are the targets for both T cell and antibody responses throughout infection *in vivo*. Hypothesizing that escape from such adaptive immune responses in Env might reveal IFITM sensitivity, we found that reversal of amino-acid changes in gp120 that arose through the escape of early neutralizing antibody responses (86) fully restored IFITM resistance to the 6-month virus. Furthermore, in primary human CD4⁺ T cells, knockdown of IFITM2 and 3 rescued much of the 6 month virus's replication after IFN-treatment. Thus it would appear that IFITM-resistance in Env is a major contributor to the overall IFN-I resistance of transmitted viruses, implying their evasion must be an important attribute for successful transmission. Moreover, once the virus

is systemically established, structural changes in Env that affect receptor/co-receptor interactions leading to IFITM sensitivity become tolerable if there is selective pressure applied by a competing adaptive immune response. This suggests that even host restrictions with a relatively small magnitude [by comparison to say APOBEC3G (87)] can have a major determining effect at transmission or in the early stages of systemic replication. Furthermore, because IFITM sensitivity appears to be dictated by Env/receptor interactions, these data further suggest a constraint on the envelope at transmission that endows it with IFN resistance, which itself may be an important consideration for vaccine design. Of note, recent studies on the adaptation of chimeric SIVs encoding HIV-1 envelopes (SHIVs) via sequential passage in macaques demonstrated a gain in IFN resistance mapping to Env, and particularly its level of virion incorporation (88, 89). Whether this is reflective of restriction by simian IFITMs, which do inhibit lentiviruses in culture (90), has yet to be determined.

The *ifitm* locus is complex and has not been well-annotated for genome wide association studies. However, SNPs in *ifitm3* have been implicated in the susceptibility to human disease. Of these, *rs12252* has generated much interest. Homozygosity for a very rare minor allele, *rs12252-C*, was strongly associated with the severity of H1N1 Swine Flu in the UK (91). This synonymous polymorphism changes a serine codon in the N-terminal cytoplasmic tail of IFITM3 from AGT to AGC. Initially, this was thought to lead to an alternatively spliced message that would express a N-terminally truncated IFITM3 protein lacking its endocytic YXX ϕ motif. Such a truncated protein localizes to the PM and does not restrict IAV entry (91). However, no evidence of such a splice variant has since been found, raising questions about how this SNP exerts its effects. Reproduction of *rs12252-C* association with IAV pathogenesis has been mixed, but in Han Chinese populations, where the allele frequency is much higher (30–40%), a clear association with flu severity has been confirmed (92–97). At present it is not known whether other SNPs in the locus are in linkage disequilibrium with *rs12252-C* that might explain such discrepancies. In the same Chinese population *rs12252-C* is also strongly associated with rapid progression during acute HIV-1 infection, and in particular elevated viral loads and CD4+ T cell loss (96). Unlike IAV pathogenesis, this association was also observed in heterozygotes, suggesting the effect of *rs12252-C* is dominant. These intriguing results further highlight the importance the IFITMs in HIV-1 pathophysiology. The elucidation of the molecular bases for these observations will provide mechanistic insight to their role in HIV restriction.

SERINE INCORPORATORS 3 AND 5

The accessory protein Nef, common to all primate lentiviruses, has a multitude of functions in HIV-1 replication (42). Nef is myristoylated and associates with the inner leaflet of the PM and endosomal membranes. Here it promotes downregulation of various membrane proteins from the cell surface, predominantly to reduce the recognition of infected cells by adaptive immune responses. The most well-studied Nef targets are CD4, and class I and II MHC molecules, which protect infected cells from antibody-dependent cellular cytotoxicity (ADCC) (98) or

recognition by antigen-specific T cells respectively, although several others have been identified (42), particularly amongst SIV Nef alleles. However, one conserved function of lentiviral Nef proteins that until recently remained unexplained, was its ability to promote the infectivity of the lentiviral virion (99).

Cells infected with HIV-1 mutants lacking Nef produce virions with reduced infectivity, even in the absence CD4 which itself interferes with envelope folding and trafficking (99). The magnitude of this CD4-independent effect on virion infectivity is variable amongst cell lines, but from lymphoid cells it can be reduced by as much as 50-fold (6). Pseudotyping virions with heterologous pH-dependent envelope proteins such as the glycoproteins from vesicular stomatitis virus or Ebola virus completely rescues the infectivity defect of HIV-1 Nef mutants (99). However, while this infectivity defect is manifest at an early entry or post-entry stage, it does not correlate with envelope incorporation into the virion. Furthermore, variations in gp120 variable domains, particularly the V1/V2 loops, affect the sensitivity of HIV-1 to Nef-dependent infectivity enhancement, implying that Nef regulates an intrinsic property of Env during the entry process (100). In keeping with this, Nef also affects the sensitivity of virions to certain neutralizing antibodies (101).

The first clue that this may be governed by a host restriction factor came from the observation that Nef interaction with dynamin 2 (dyn2), the major cellular GTPase that controls endocytosis, was essential to regulate particle infectivity (102). The requirement for dyn2 by Nef was during viral production, and its knockdown reduced virion infectivity to that of the Nef-defective mutant. Since Nef mediates the removal of other membrane proteins from the cell surface, one attractive hypothesis was that it was targeting an inhibitor of virion infectivity. This was further evidenced by the demonstration that in heterokaryons between human cells that had a high and low dependence on Nef for virion infectivity, the requirement for Nef was dominant (6). Intriguingly, the accessory protein of gamma retroviruses, a membrane-bound and glycosylated form of their major structural protein Gag (GlycoGag), can substitute for Nef activity and vice versa (103). GlycoGag is generated from a weak in-frame translational start site upstream of the regular Gag initiation codon, producing a Gag with an 88 amino acid N-terminal extension that results in its insertion in the ER membrane. As with Nef, GlycoGag promotes MLV infectivity in a dyn2 and endocytosis dependent manner (104), thus indicating that they target a common factor or pathway.

In 2015 two groups cloned the factor(s) responsible for this phenotype by complementary approaches. In the first, Massimo Pizzato and colleagues performed a large scale gene expression analysis of cells where the virus dependence on Nef varied, looking for mRNAs whose abundance correlated with the magnitude of the infectivity enhancement (6). In the second, Heinrich Gottlinger's group performed proteomic analyses of HIV-1 virions purified from human T cells in the presence or absence of Nef and/or GlycoGag expression, hypothesizing that a Nef-regulated inhibitor of infectivity may be incorporated into virions of Nef-defective viruses (8). Both groups identified members of the serine incorporator (SERINC) family of multi-pass membrane transporters, SERINC5 and SERINC3 respectively. Shortly afterward, a further proteomic study documenting global

changes to the cell surface proteome of HIV-1 infected T cell lines identified both SERINC5 as differentially regulated by wild-type and Nef-defective viruses (105). Both proteins were shown to inhibit Nef-defective virus infectivity upon ectopic expression in “low Nef-responsive” cells, with SERINC5 being the most potent (6, 8, 106). Conversely, CRISPR/Cas9 knockout of both SERINC5 and SERINC3 fully restored Nef-defective virus infectivity from CD4+ T cells. In the presence of Nef, SERINC5 is relocalized from the PM to endosomal compartments dependent on Nef interaction with the clathrin adaptor AP-2 (**Figure 2B**). Moreover, SERINC5 was also counteracted by various SIV Nef alleles as well as MLV GlycoGag and VSV-G (6, 8), thus recapitulating the known features of the proposed restriction factor. Additionally, the S2 accessory protein of the distantly related lentivirus, equine infectious anemia virus (EIAV), also counteracts SERINC5 (107). Interestingly, unlike the IFITMs or tetherin (see below), SERINC5 are neither significantly regulated by IFN-I, nor do they display evidence of positive selection in mammals (6, 108).

At the time of writing almost nothing is known about the mechanism by which SERINC5 exerts its antiviral activity. SERINC5 are PM proteins with 12 predicted TM domains (**Figure 1B**). They are conserved from yeast to man, but only SERINC3 and 5 restrict retroviral infectivity (6, 8). Whilst there are several predicted isoforms of SERINC5 derived from putative splice variants, the majority mRNA species encodes the longest form (109). SERINC5 were originally named for their proposed ability to incorporate serine into membranes as phosphatidylserine or sphingolipids (110), although how they do this or even whether this activity is relevant for viral restriction is not known. Direct incorporation of SERINC5 into the virion seems to be essential, and as a result of Nef-mediated internalization, SERINC5 is excluded from the assembling virion (6, 8, 111). However, this is not sufficient to explain the antiviral activity as VSV-G pseudotyping of the virus confers complete SERINC5 resistance without blocking incorporation (6, 8). What has been shown is that the block mediated by SERINC5 occurs at the fusion stage (6, 8). Both particle-associated beta-lactamase (BLAM) or CRE recombinase transfer to target cells is reduced in the presence of SERINC5, however the magnitude of this block to fusion does not fully match that of the infectivity defect or levels of reverse transcription. Whilst this has been interpreted as a potential block to fusion pore expansion rather than the initiation of fusion, it could also simply be a reflection of the difference in the dynamic range of assays that measure entry and post-entry events. Interestingly, SERINC5 sensitivity of primary R5 tropic viruses is variable in the absence of Nef (8). Exchange of the gp120 V1/V2 or V3 loops between these and prototypic X4 viruses swaps these phenotypes. This in part maps to variable N-linked-glycosylation sites in gp120 that are thought to stabilize the envelope glycoprotein (100). A very recent study indicates that while there is no evidence yet of direct Env/SERINC5 interaction, sensitive envelopes appear to be inactivated, exposing epitopes that would normally require receptor interactions (112, 113). Thus SERINC5 may be affecting the intrinsic stability of the Env trimer, thus blocking fusion. It is interesting to note the potential parallels here with those of the restriction of HIV-1 by IFITMs, with the relative resistance of R5 envelopes again highlighting that constraints on the envelope

glycoprotein may be driven by selection for their resistance to intrinsic antiviral restriction mechanisms.

As noted above, SERINC3/5 expression appear not to be regulated by inflammatory stimuli and there is no evidence of the positive selection in mammalian SERINC5 that is a common feature of other viral restriction factors (6). There is no apparent species specificity in antagonism, with a given HIV-1, HIV-2 or SIV Nef counteracting both human and primate SERINC5 orthologues (114). This conservation of function in Nef would in itself imply its importance. However, further observations have hinted that the efficiency of Nef-mediated SERINC antagonism by HIV and SIV Nef alleles may correlate with prevalence of a given virus in its host primate species (114). If so, then the selective pressure on Nef that gives rise to this variation in activity will be more complex than simply Nef/SERINC5 interaction, and may reflect, for example, impacts of envelope variation in SIVs or other properties of SERINC5 in lentiviral replication yet to be discovered.

OTHER LENTIVIRAL “ROUTE OF ENTRY” RESTRICTIONS

Aside from IFITMs and SERINC5, other restrictions have been reported that affect post-entry events in lentiviral replication dependent on the route of viral entry. These restrictions, termed Lv2 and Lv3 [Lv1 being the name of the post-entry restriction activity later shown to be conferred by species-specific variants of TRIM5 α (115, 116)], operate in human and primate cells respectively. Lv2 manifests as a block to reverse transcription and nuclear entry, and was originally demonstrated for HIV-2 in certain human cell lines and primary macrophages (**Figure 2C**) (117). The viral determinants of this restriction mapped both to the viral capsid and envelope proteins, but the entire restriction can be bypassed by VSV-G, suggesting that the post-entry block depends on where in the cell the virus fuses (118). Consistent with this, Lv2 restriction can be relieved by blocking endocytosis or mis-localizing CD4 at the PM (119). Moreover, these restriction patterns can also be seen for a variety of X4-using HIV-1 strains and be in part conferred to a heterologous core by envelope pseudotyping (119), a phenotype that bears some similarity to those for IFITM-mediated restriction (80). However, more recently regulation of nuclear pre-mRNA domain-containing protein 2 (RPRD2), termed by the authors REAF (RNA-associated early stage antiviral factor), has been proposed to be the effector of Lv2 restriction (120, 121). REAF appears to interact with the incoming genome to block reverse transcription, but is dependent on the pseudotyping envelope (**Figure 2C**). Whether REAF is differentially localized along the endocytic network, or whether restrictions during fusion (or avoidance thereof) predispose the incoming virus to REAF-mediated restriction remains to be determined. Similarly, Lv3 is a post-entry block to HIV replication in macaque cells that is distinct from TRIM5 α and again depends on the Env CD4/coreceptor interactions (122). Again, this bears superficial similarities to IFITM restrictions, but the block appears to be manifest at reverse transcription and can be saturated (**Figure 2C**).

A third very recent example of “route of entry restrictions” has been described in a human dendritic cell subset, Langerhans cells (LCs), that are resistant to HIV-1 infection due to the interaction between the virus and the C-type lectin langerin (123). This mediates virion targeting to Birbeck granules and prevents viral replication at an early post-entry stage. This turns out to be dependent on human TRIM5 α , the capsid-binding restriction factor to which HIV-1 was thought to be resistant. In the presence of langerin, the authors propose that TRIM5 α is recruited to the site of entry and targets the incoming virus to an autophagic degradation pathway. In other DC subsets, virion engagement with a different lectin, DC-SIGN, prevents the recruitment of TRIM5 α upon virion internalization (**Figure 2C**).

Type II IFNs (IFN γ) have an under-appreciated direct antiviral activity on HIV-1 (124). In part, this again maps to the envelope protein, and in particular the V1/V2 loop (124). The initial results suggest that TF viruses may be more resistant to the effects of IFN γ , but the factors involved are not yet known.

TETHERIN

At the other end of the viral lifecycle, the most prominent antiviral inhibitor of lentiviral replication associated with the plasma membrane is tetherin (also known as bone marrow stromal cell antigen 2—BST2 or CD317). Tetherin’s antiviral activity was discovered as the target of the HIV-1 accessory protein Vpu (125, 126), long known to play a role in the efficient release of new retroviral particles from infected cells. Tetherin is an IFN- and pattern recognition-regulated gene and has a general antiviral function against diverse enveloped viruses [reviewed in Ref. (5)]. Amongst the primate lentiviruses, tetherin antagonism is a highly conserved attribute (127). Furthermore, the adaptation of HIV-1 Vpu to target the human tetherin orthologue was a key event in the development of the HIV/AIDS pandemic. In this section we will focus only on the role of tetherin in lentiviral pathogenesis.

Tetherin-Mediated Restriction of Viral Release

Tetherin is a type 2 membrane protein whose distinctive topology is indicative of its primary mode of action: the retention of fully-formed virions on the PM of infected cells and their subsequent removal to endosomes (128, 129). Tetherin exists in the PM as disulfide-linked dimers that constitutively recycle via the Golgi apparatus (130, 131). The extracellular domain of tetherin forms a rod-like coiled-coil, with a hinge towards its N-terminal transmembrane domain to allow a degree of rotational flexibility (**Figure 1C**) (132–134). The C-terminus is covalently attached to the lipid of the PM by a glycosylphosphatidylinositol (GPI) linkage, giving the mature protein two membrane anchors (**Figure 1C**) (128, 130). As the nascent virus buds through the PM, tetherin dimers are recruited to the virion membrane (128, 135, 136). The C-terminal GPI anchor appears to be preferentially incorporated into the virion whilst the N-terminal TM domain is retained outside the bud (**Figure 3**) (129). When the ESCRT pathway mediates the scission of viral and cellular membranes, tetherin dimers retain the new viral particle via a stable protease-sensitive

crosslink (125, 129, 137, 138). Leaky scanning of the tetherin mRNA leads to two isoforms being expressed at apparently equal levels, differing in the length of their cytoplasmic tails (139). Depending on the species orthologue, the shorter isoform lacks the first 12–17 amino acids that encompass the major subcellular trafficking signal—a dual tyrosine-based motif that engages clathrin adaptors AP1 and AP2 (131). Both isoforms can form homo- and heterodimers and both can potentially restrict viral release (139, 140). However, the longer human isoform has a pro-inflammatory signalling activity associated with it (see below), and is also more sensitive to Vpu (139, 140).

Tetherin expression is induced by both type I and II IFNs, as well as pattern recognition signals, in many cell types (141, 142). It is expressed on activated T cells and is constitutively expressed by plasmacytoid dendritic cells. Tetherin expression is upregulated on peripheral blood mononuclear cells during the acute phase of HIV infection (143), and by treatment of HIV-infected individuals with IFN α (45). Its expression is enriched on tissues with barrier function, further suggesting an important role in host defence (144).


Tetherin Counteraction by Primate Lentiviruses and Its Role in Limiting Cross-Species Transmission

Tetherin targets a part of the virus that it cannot mutate to evade restriction, therefore the virus must evolve a countermeasure. Although the virally-encoded protagonist and mechanism differ, the ability to counteract tetherin is conserved among primate lentiviruses (5).

SIVs are naturally prevalent in a wide range of African non-human primates [reviewed in Ref. (145)]. For the most part each species is infected with a monophyletic strain of SIV (indicated by a suffix denoting the host species e.g. SIV_{smm} in sooty mangabeys), signifying predominantly within-species spread, with some notable examples of cross-species transmissions. Over 40 primate lentiviruses have been identified, and of these three have crossed the species barrier into humans: SIV_{cpz}, SIV_{gor} and SIV_{smm}, from chimpanzees, gorillas and sooty mangabeys respectively (145).

The precursors to HIV-1 were transmitted from chimpanzees to humans on at least 2 separate occasions, giving rise to HIV-1 groups M and N (146, 147), and twice from gorillas to humans resulting in HIV-1 groups O and P (148, 149). The precursors to HIV-2 crossed from sooty mangabeys into humans at least 8 different times (or at least their sequence diversity suggests independent cross-transmissions), resulting in HIV-2 groups A–H (150–152). These 12 groups of viruses have had vastly different impacts on the human population, ranging from single-case HIV-2 infections to the millions of people infected with Group M since its first predicted zoonotic infection in the early 1900s (145). While environmental and social factors inevitably played a role in the outcome of these zoonoses, extensive work dissecting host-pathogen relationships reveals a role for tetherin in influencing the course of cross-species infections.

Most SIVs counteract their host’s tetherin using the accessory protein Nef (127, 153, 154). Notable exceptions to this are SIVs



from greater spot-nosed, mustached and mona monkeys (SIVgsn, mus and mon respectively) which are unique among SIVs in possessing the accessory protein Vpu, capable of antagonising tetherin in a species-specific manner (127). Although SIVcpzPtt and SIVgor are also among the subset of SIVs that possess a *vpu* gene, their Vpus lack the ability to counteract chimpanzee, gorilla and human tetherin, although they still maintain function in the form of robust CD4 downregulation (127). These viruses use Nef as an antagonist, which stimulates the AP2-dependent clathrin-mediated endocytosis of tetherin, removing it from the site of virus assembly. The use of Nef rather than Vpu as a tetherin antagonist may be explained by the origins of SIVcpz—a chimeric virus originating from recombination between an ancestral strain of the SIVgsn/mus/mon lineage and red-capped mangabey SIV (SIVrcm) (155). Inheriting two tetherin antagonists appears to have resulted in SIVcpz losing counteractivity in one.

The deletion of a five amino acid stretch (G/DIWKK) in the cytoplasmic tail of tetherin (Figure 3) between 1 and 6 million years ago—after divergence from chimpanzees but before the divergence of Denisovans and Neanderthals—has rendered the

human protein resistant to SIV Nef antagonism (127, 153, 154, 156). Consequently, establishing a successful infection in humans requires an alternative mechanism of tetherin counteraction, either by adapting a different antagonist or adjusting the action of Nef. As detailed below, the mechanism and/or the extent of the adaptation differs in each known case of cross-species transmission.

HIV-1 group M Vpu efficiently deals with both tetherin's physical virus restriction and subsequent antiviral signalling by escorting nascent tetherin into a defunct cellular pathway and triggering its degradation (5). Vpu and tetherin interact via their transmembrane domains, with the interactive face of Vpu consisting of highly conserved alanines and a tryptophan (Figure 3) (157–160). Moreover, it is this interacting face that was likely to have been the key adaptation that led to human tetherin counteraction by the prototypic group M HIV-1 as revealed by the Vpu sequences of its closest extant SIVcpzPTT relatives (161). Tetherin/Vpu complexes are then targeted to late endosomes for degradation (162). This complex process requires the phosphorylation of the Vpu cytoplasmic tail that facilitates

the formation of a ternary complex between tetherin, Vpu and the clathrin adaptor AP-1, and perhaps AP-2, promoting their targeting to late endosomes (163–165). This mechanism allows Vpu to engage both newly synthesized and recycling tetherin pools. Concomitant with this process, the dual-serine phosphorylation site of Vpu, a conserved DSGxxS motif, interacts with an SCF E3 ubiquitin ligase, predominantly through the adaptor protein β TRCP2 (162, 166–169). This leads to multiple ubiquitination events in the Vpu cytoplasmic tail (170–172) that target it for ESCRT-mediated degradation (164, 173–175). This final rerouting and degradation of tetherin requires the major endocytic motif in its cytoplasmic tail (163, 175). Thus the short isoform of tetherin cannot be degraded or downregulated from the surface by Vpu (140). However, physical interaction with Vpu does reduce its incorporation into virions, counteracting tetherin at lower expression levels.

Primary HIV-1 group M Vpus are highly active antagonists of tetherin and efficient inhibitors of tetherin-mediated NF- κ B signalling, and these functions are conserved in transmitted viruses and throughout the course of infection, and across the clades (127, 176–178). Suboptimal Vpus are rapidly selected against *in vivo*, and robust anti-tetherin function is maintained even years after infection (177). Studies of viruses with mutations in Vpu rendering them specifically unable to counteract tetherin but otherwise unaffected, demonstrate that these viruses are compromised compared to wildtype viruses in the presence of high concentrations of IFN-I (179). Likewise, selective pressure provided by upregulated tetherin expression during IFN α treatment of HIV-infected individuals may select for changes in Vpu (45). Thus, Vpu-mediated tetherin counteraction contributes to the overall viral interferon resistance.

Interestingly, it appears that Group M Nefs are able to acquire moderate ability to counteract human tetherin in certain circumstances (180). Although this does not represent a common activity amongst Group M Nefs, the association of a proportion of the active Nefs with viruses harbouring defective Vpus further underlines the importance of tetherin antagonism *in vivo* (180).

Fewer than 20 cases of Group N infections have been documented to date, and their adaptation to human tetherin represents a mixed and developing picture. For the most part they display some ability to counteract tetherin and enhance infectious virus release from cells, but activity is poor compared to the typical levels of Group M Vpus (127). However, a highly pathogenic Group N virus isolated from a French individual—the first case of Group N infection found outside Cameroon—demonstrated Vpu activity on a par with that of Group M. This French/Togo Vpu contains functional domains known to contribute to activity in Group M Vpus, whilst these are lacking in other known weak Group N Vpus (181). The mixed success of Group N Vpus to combat human tetherin is counterbalanced by its total inability to perform another major function of Vpu, the downregulation of CD4.

HIV-1 Group O infections represent a substantial epidemic, with an estimated 100,000 people infected. The majority of Group O Vpus tested demonstrate poor tetherin antagonism (127, 182, 183); instead, Group O Nef has adapted to target a different region of human tetherin, circumventing the 5 amino acid deletion that confers resistance to inhibition by SIV Nefs (184). The activity of

the Group O Nefs is species-specific, being more efficient at down-modulating human compared to gorilla tetherin. Interestingly, a single example of a Group O Vpu able to counteract tetherin has recently been reported (185).

HIV-1 group P viruses have been isolated from only two individuals to date, both from Cameroon (186, 187). These viruses appear to be poorly adapted to humans, with no tetherin counteractivity detected in either their Vpu, Nef or Env proteins (183, 188).

Like most SIVs, the SIVsmm precursor to HIV-2 uses Nef to antagonise tetherin in its sooty mangabey host (127). Similar to SERINC5 antagonism, SIV Nefs bind to their cognate primate tetherin dependent on the G/DWIKK motif and promote its AP-2-mediated endocytosis from the cell surface (189, 190). While HIV-1 Group M evolved efficient tetherin antagonism by Vpu, and Group O Nefs evolved to target a different region of tetherin (184), HIV-2 employs a different strategy of antagonism, using the Env protein (191). The extracellular domains of both proteins interact, and again this stimulates endocytic removal of tetherin from the cell surface through Env's interaction with AP-2 (191–194). Tetherin antagonism appears to be a conserved attribute of HIV-2 isolates tested to date (195), although the potency of HIV-2 Env in enhancing virus release is weaker than that of HIV-1 group M Vpus, insofar as *in vitro* assays are a true reflection of activity. Whether there is a fitness and efficacy cost associated with using a major structural protein, also under pressure to evade antibody responses, to carry out a role more commonly performed by accessory proteins remains to be seen.

In Vivo Relevance—Evidence from Experimental Infections

The importance of tetherin *in vivo* is demonstrated by the remarkably diverse strategies enlisted by viruses to overcome this barrier (5). Simple demonstrations of this arms race in action come from experimental infections of primates, of which there are several examples demonstrating pathogenesis associated with acquisition of tetherin counteractivity. Studies of chimpanzees infected with HIV-1 for the purposes of vaccine studies in the 1980s were revisited in order to investigate readaptation to a previous host species. Examination of the readapted viruses revealed that, although the Vpu maintained function, tetherin antagonism was also acquired in Nef, with the virus using both proteins to overcome chimpanzee tetherin (196). The minimal changes required to restore anti-chimpanzee tetherin activity to the HIV-1 Nef were just 2 amino acids, and the region of chimpanzee tetherin targeted by the adapted Nef was mapped to the DIWKK region deleted in human tetherin (196). It therefore appears that lost accessory gene functions can be reacquired relatively easily. Similarly, serial passage of modified simian tropic HIV-1 in pigtail macaques resulted in a virus that could replicate efficiently and cause AIDS in these otherwise unsusceptible hosts (197). The modified virus used in the original inoculum was endowed with resistance to macaque APOBEC3 restriction factors, but unable to counteract monkey tetherins. Four passages resulted in a pathogenic virus that was able to efficiently counteract macaque tetherin while maintaining anti-human tetherin activity. The amino acid changes responsible

for this adaptation were mapped to the transmembrane region of the Vpu—the region that interacts with tetherin—and involved only two amino acid changes (197).

Infection of rhesus macaques with Nef-deleted SIV (SIVmac Δ nef) usually results in attenuated infection, with persistent but low-level viral replication. After serial passage these viruses can revert to pathogenicity, leading to high viral loads and progression to disease (198). Analyses of the pathogenic revertant viruses confirmed that these viruses had adapted to counteract rhesus tetherin, with determinants mapping to the cytoplasmic tail of the envelope protein gp41. The minimal changes required to endow Env with this Nef-like activity involved just five amino acids (199). Acquisition of tetherin counteraction in SIV envelopes has been documented in the SIVtan envelope, most likely through passage in human cells (200). More recently, such an adaptation has also been observed in an *in vivo* for a highly neurotropic SIVsm (201).

Studies in tetherin knock-out mice provide direct evidence of tetherin's antiviral role *in vivo*, with increased replication and pathogenicity of a murine retrovirus observed in the absence of tetherin (202). Otherwise normal development of $-/-$ mice, including no detectable adverse effects on the immune system, further support the primary function of tetherin as an antiviral effector protein. Indeed, most mammalian tetherin orthologues possess antiviral activity, and the role of tetherin as an ancient immune effector molecule is supported by the demonstration of identifiable tetherin orthologues with antiviral activity in reptiles and as far back as the coelacanths (203, 204).

Tetherin's Role in Linking Innate and Adaptive Immunity

Tethering viruses to the producer cell membranes and preventing their release is an obvious obstruction to virus propagation. However, the major mode of HIV transmission in cultured T cells is via synaptic conjugations between infected and uninfected cells. These virological synapses are driven by Env/CD4 interactions and result in polarized secretion of new virions across the synaptic cleft (205). While very potent at blocking cell free virus release, the inhibitory effects of tetherin on cell-to-cell spread via the virological synapse structures is weak. In primary human CD4 $^{+}$ T cells, Vpu-defective viruses even spread faster due to tetherin-mediated cell-associated virus accumulation, despite lower cell-free virion release (206). Given the high selection pressure to maintain tetherin counteraction in lentiviruses, it has therefore been of particular interest to determine whether the consequences of restriction have wider ramifications than simply the physical prevention of dissemination. Viruses tethered to the cell surface are exposed to anti-Env antibodies, particularly those targeting CD4-induced epitopes, and this sensitizes the infected cell to ADCC-mediated elimination by Fc-receptor bearing myeloid and NK cells (**Figure 3**) (98, 207–209). This effect is enhanced by treatment of cells with IFN α due to increased tetherin expression. In turn it is effectively suppressed by HIV-1 Vpu and Nef, which play dual roles by counteracting tetherin and by degrading CD4, therefore protecting the nascent Env trimers from exposing CD4-dependent epitopes and reducing the

numbers of cell-associated virions (98, 207–209). Importantly, tetherin therefore acts as a link between innate and adaptive immunity, enhancing the potency of antiviral antibodies and increasing the pressure on the virus to maintain efficient tetherin antagonism.

The clustering of cell surface tetherin molecules due to virus retention triggers signalling events mediated by its cytoplasmic tail, leading to NF- κ B activation and the release of pro-inflammatory cytokines (139, 210, 211). These cytokines could potentially serve to further amplify tetherin's role in ADCC by recruiting effector cells to the site of infection. Tetherin's signaling activity is restricted to homodimers of the long isoform (139). In this context the major endocytic site, a dual tyrosine motif YDYCRV, acts as a hemi-immuno-tyrosine activation motif (212). Upon virion retention, tyrosines on both L-tetherin monomers become phosphorylated by Src-family kinases and present an SH2-domain for the recruitment of the kinase Syk (212). This in turn recruits a signaling complex including TRAF2, TRAF6 and TAK1, ultimately activating NF- κ B (**Figure 3**) (211, 212). Thus in addition to retaining virions at the cell surface, tetherin acts akin to a pattern recognition receptor in sensing virus restriction. This sensing is dependent on tetherin's link to the cortical actin cytoskeleton via an adaptor protein RICH2 (AHRGAP44) (212, 213). There appears to be some primate species specificity in tetherin's signaling activity. The deletion that occurred in chimpanzee tetherin that rendered the human orthologue resistant to Nef antagonism, and serves as a highly effective barrier to cross-species transmissions, also appears to have contributed to the efficiency with which human tetherin initiates proinflammatory signalling (210). In human cells this correlates with primate tetherin phosphorylation efficiency and Syk recruitment (212). Whether this is truly an neofunctionalization of tetherin during primate evolution, or reflects species incompatibilities in experimental cellular systems is not clear. However, in mice knocked-in for constitutive somatic human tetherin expression, runting and early lethality is observed consistent with chronic inflammatory signaling (214).

A further intriguing link between tetherin and innate sensing of viruses is its identification as a ligand for the leukocyte inhibitory receptor, ILT7, expressed on plasmacytoid dendritic cells (pDCs). Interaction between tetherin and ILT7 induces an inhibitory signal that dampens responses by TLR ligands (**Figure 3**) (215). Recent data from the Cohen group suggests that the ILT7/tetherin interaction acts akin to a 'missing self' signal when a pDC encounters a cell infected with a tetherin-sensitive virus (216). The recruitment of tetherin into budding virions occludes its ability to interact with ILT7 on the pDC, thereby enhancing the responsiveness of the pDC if simultaneously encountering extracellular RNA. The authors postulate that differential surface removal of long and short tetherin isoforms by HIV-1 group M Vpu (and some extent Group O Nefs) ensures a sufficient pool tetherin at the PM to deliver this inhibitory signal at the same time as counteracting its antiviral effects (216, 217). Whether this is a universal function of tetherin is unclear; mice lack an ILT7, and a functional orthologue has yet to be identified. However, the upregulation of tetherin on some cancers may suggest that ILT7 interaction is important for tumor-cell immune evasion (215).

Together these observations indicate that tetherin's antiviral activity *in vivo* is not limited to the physical reduction in cell free virus produced from the infected cell. Rather, virion-tethering to the cell has important knock-on effects on how it is perceived and dealt with by both the innate and adaptive immune response. This linkage between direct antiviral activity and the augmentation of downstream immune responses would thus further explain the high level of selective pressure on viruses such as HIV-1 not only to counteract tetherin for efficient transmission, but to maintain this activity after the establishment of systemic infection where the physical impairment of viral release has only minor effects on spread to new target cells.

OTHER INHIBITORS OF HIV-1 RELEASE AND ASSEMBLY AT THE PLASMA MEMBRANE

Whilst the most prominent, tetherin is unlikely to be the only antiviral factor that targets HIV during the assembly and release stage. In principle many adhesion molecules or lectins could exert an antiviral effect on virus release provided they, or their ligand, are incorporated into viral particles. Indeed, in the absence of both Vpu and Nef, CD4/Env interactions can limit HIV release (218) as well as exposing epitopes for ADCC.

The T-cell immunoglobulin and mucin domain (TIM) family of phosphatidylserine (PS) receptors have been implicated as important attachment for a variety of enveloped viruses (219). The exposure of PS on the surface of the PM of apoptotic cells (220) is important for their clearance by phagocytes, and it is thought that diverse enveloped viruses hijack PS exposure to facilitate attachment and entry into target cells (219). TIM family members are variably expressed on myeloid and activated T cell subsets. In the case of HIV-1, expression of TIM-1 in target cells enhances virion entry. This may be by upregulating CD4/coreceptor levels, but very recent evidence has shown that PS exposure on the target cell is important for HIV-1 fusion. Conversely, overexpression of TIM family members restricts virion release by mediating a phenotype remarkably similar to tetherin (220). Of note, TIM-3 silencing in primary macrophages enhances virion release 2–4 fold, suggesting these observations maybe of relevance *in vivo*. Interestingly, the mucin domain of TIM-1 is highly polymorphic and homozygosity for a 6 amino acid in-frame deletion variant (delMTTTPV) has been associated with reduced HIV-1 disease progression (221) and replication in *ex vivo* cultured CD4+ T cells (222). Whether this is because of an inhibitory effect or a reduced entry-enhancing activity is yet to be determined.

The inhibition of processing and incorporation of Env into nascent virions was suggested as an antiviral mechanism of IFN-I against HIV-1 many years ago (223). Recent studies have implicated this process as a target for two ISGs (224, 225). LGALS3BP/90K, a cysteine rich secreted scavenger receptor that has a role in regulating cell adhesion, is strongly upregulated by IFN-I and IFN-II and is present at high concentrations in most bodily fluids. Expression of cell-associated 90K blocked envelope incorporation and gp160 processing dependent on its BR-C, ttk, BOZ/Poxvirus Zinc finger (BTB/POZ) domain (225). 90K does

not generally inhibit furin-like proteases that cleave a number of viral glycoproteins, nor does it have antiviral activity against murine retroviruses. Neither was 90K found to directly associate with gp160 in the secretory pathway. However, 90K depletion in both T cells and macrophages enhanced HIV-1 replication. A similar activity has been associated with guanylate binding protein 5 (GBP5), a member of a family of IFN-induced GTPases (224). As with 90K, expression of GBP5 blocked the processing and incorporation of gp160 as well as other retroviral envelope proteins. This required the ability of GBP-5 to localize to the Golgi network, but appears independent of its GTPase activity. Furthermore, GBP5 expression levels in primary macrophages inversely correlated with viral replication. Interestingly, Env expression levels were a key to HIV-1 GBP-5 sensitivity. Mutations in the start codon of *vpu*, which is expressed from the same mRNA, enhances Env expression levels and confers partial GBP5 resistance. Since Vpu is essential to counteract tetherin (see below), the authors speculate that balancing the expression of Vpu and Env allows for optimal viral replication in the face of these two IFN-induced restrictions. As yet, little further mechanistic understanding of 90K or GBP-5-mediated effects on Env are known, or indeed whether they are related given their phenotypic similarities.

The assembly and budding of the nascent virion at the PM has been suggested as a target for IFN-I-mediated restriction. 2',3'-cyclic-nucleotide 3'-phosphodiesterase (CNP) was identified in an overexpression screen of ISGs that restrict viral release (226). CNP, a membrane-associated enzyme, bound to Gag in membrane fractions and inhibited particle formation independent of its enzymatic activity. While most mammalian CNP orthologues tested had antiviral activity against HIV-1, a single amino acid difference in murine CNP accounted for its lack of retroviral restriction. Selection of CNP-resistant viruses resulted in a single point mutation (E40K) in the matrix (MA) domain of the Gag polyprotein, which alongside the murine CNP species-specific difference, governed CNP/Gag interactions. Interestingly, the equivalent position in MA is a K in some HIV-2 and SIV isolates and this correlates with their resistance to CNP. However, whether CNP ever gets the opportunity to restrict HIV-1 *in vivo* is unclear. It is expressed mainly in oligodendrocytes and epithelial cells, with some expression in DCs, but is not detectable in primary CD4+ T cells.

Finally, the ESCRT-mediated release of the virus has been suggested as a target of IFN-mediated restriction. The interferon-induced ubiquitin-like modifier, ISG15, has a broad role in antiviral defence (227). The ESCRT-III complex constricts the neck of the budding virion to the point of scission. This requires the polymerization of its charged multivesicular protein (CHMP) components into helical polymers on the internal surface of the neck, followed by their regulated disassembly by the AAA-ATPase VPS4 and its cofactor, LIP5 (4). Direct conjugation of ISG15 (ISGylation) to various CHMPs blocks their interaction with VPS4/LIP5, thereby stalling retrovirus budding (228, 229). ISGylation of CHMP5 appears to be essential for this process as in its absence, no other CHMP becomes modified (228). CHMP5 is dispensable for ESCRT-III function itself, raising the possibility that it is a regulator that can rapidly inhibit ESCRT

function after IFN treatment. Whether CHMP5 ISGylation is a major mechanism of antiretroviral defence under physiological conditions is not yet clear. Another ESCRT-III regulating factor, CC2D1A, binds to the ESCRT-III CHMP4B and blocks polymer formation, thereby dominantly interfering with HIV-1 assembly (230, 231). CC2D1A itself is an ISG (7), although whether it acts in a directly antiviral capacity is not known given that it has also been identified as a regulator of TBK1, a major kinase in the pattern recognition signaling cascade (232).

CONCLUDING REMARKS

Negotiating the limiting membranes of the cell represent the first and last stages of HIV-1 replication. As analogous processes are common to all enveloped viruses, the evolution of antiviral factors that inhibit them present general first line defences against HIV-1 and related viruses. Their importance is reflected in the

resistance mechanisms that primate lentiviruses have evolved to avoid them, and the evidence that their antiviral activities present significant barriers to viral transmission, systemic spread and augmentation of other immune responses. This suggests that targeting the virus's resistance to PM-based host restrictions may have therapeutic or vaccine-relevant potential. Their study also reveals fundamental new understanding of the basic processes of viral entry and exit from the cell.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

FUNDING

The Neil laboratory is funded by the Wellcome Trust.

REFERENCES

- Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. *Molecular Biology of the Cell*. 6th ed. New York: Garland Science (2014).
- Helenius A, Moss B. Virus entry – an unwilling collaboration by the cell. *Curr Opin Virol* (2013) 3:1–2. doi:10.1016/j.coviro.2013.01.003
- Yamauchi Y, Helenius A. Virus entry at a glance. *J Cell Sci* (2013) 126:1289–95. doi:10.1242/jcs.119685
- Martin-Serrano J, Neil SJ. Host factors involved in retroviral budding and release. *Nat Rev Microbiol* (2011) 9:519–31. doi:10.1038/nrmicro2596
- Neil SJ. The antiviral activities of tetherin. *Curr Top Microbiol Immunol* (2013) 371:67–104. doi:10.1007/978-3-642-37765-5_3
- Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, et al. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. *Nature* (2015) 526:212–7. doi:10.1038/nature15399
- Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. A diverse range of gene products are effectors of the type I interferon antiviral response. *Nature* (2011) 472:481–5. doi:10.1038/nature09907
- Usami Y, Wu Y, Gottlinger HG. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. *Nature* (2015) 526:218–23. doi:10.1038/nature15400
- Wilen CB, Tilton JC, Doms RW. HIV: cell binding and entry. *Cold Spring Harb Perspect Med* (2012) 2:a006866. doi:10.1101/cshperspect.a006866
- Ward AB, Wilson IA. The HIV-1 envelope glycoprotein structure: nailing down a moving target. *Immunol Rev* (2017) 275:21–32. doi:10.1111/imr.12507
- Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grise H, et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. *Nature* (2006) 441:847–52. doi:10.1038/nature04817
- Chojnacki J, Staudt T, Glass B, Bingen P, Engelhardt J, Anders M, et al. Maturation-dependent HIV-1 surface protein redistribution revealed by fluorescence nanoscopy. *Science* (2012) 338:524–8. doi:10.1126/science.1226359
- Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, Weiss RA. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. *Nature* (1984) 312:763–7. doi:10.1038/312763a0
- Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, Herrendt T, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. *Nature* (1984) 312:767–8. doi:10.1038/312767a0
- Maddon PJ, McDougal JS, Clapham PR, Dalgleish AG, Jamal S, Weiss RA, et al. HIV infection does not require endocytosis of its receptor, CD4. *Cell* (1988) 54:865–74. doi:10.1016/S0092-8674(88)91241-X
- Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* (1998) 393:648–59. doi:10.1038/31405
- Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. *Science* (1998) 280:1949–53. doi:10.1126/science.280.5371.1949
- Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. *Nature* (1998) 393:705–11. doi:10.1038/31514
- Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. *Science* (1996) 272:1955–8. doi:10.1126/science.272.5270.1955
- Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al. Identification of a major co-receptor for primary isolates of HIV-1. *Nature* (1996) 381:661–6. doi:10.1038/381661a0
- Dragic T, Litwin V, Allaway GP, Martin SR, Huang Y, Nagashima KA, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. *Nature* (1996) 381:667–73. doi:10.1038/381667a0
- Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. *Science* (1996) 272:872–7. doi:10.1126/science.272.5263.872
- Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. *Cell* (1996) 85:1149–58. doi:10.1016/S0092-8674(00)81314-8
- Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proc Natl Acad Sci U S A* (2008) 105:7552–7. doi:10.1073/pnas.0802203105
- Margolis L, Shattock R. Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? *Nat Rev Microbiol* (2006) 4:312–7. doi:10.1038/nrmicro1427
- Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. *Cell* (1996) 86:367–77. doi:10.1016/S0092-8674(00)80110-5
- Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. *Nature* (1996) 382:722–5. doi:10.1038/382722a0
- Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, Hsueh J, et al. A prominent site of antibody vulnerability on HIV envelope incorporates a

- motif associated with CCR5 binding and its camouflaging glycans. *Immunity* (2016) 45:31–45. doi:10.1016/j.immuni.2016.06.026
29. Duenas-Decamp MJ, Peters PJ, Repik A, Musich T, Gonzalez-Perez MP, Caron C, et al. Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. *Future Virol* (2010) 5:435–51. doi:10.2217/fvl.10.34
 30. Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. *J Virol* (2014) 88:1858–69. doi:10.1128/JVI.02477-13
 31. Parrish NE, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH, et al. Phenotypic properties of transmitted founder HIV-1. *Proc Natl Acad Sci U S A* (2013) 110:6626–33. doi:10.1073/pnas.1304288110
 32. Simmons G, Reeves JD, McKnight A, Dejuic N, Hibbitts S, Power CA, et al. CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. *J Virol* (1998) 72:8453–7.
 33. McClure MO, Marsh M, Weiss RA. Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. *EMBO J* (1988) 7:513–8.
 34. Pelchen-Matthews A, Clapham P, Marsh M. Role of CD4 endocytosis in human immunodeficiency virus infection. *J Virol* (1995) 69:8164–8.
 35. Miyauchi K, Kim Y, Latinovic O, Morozov V, Melikyan GB. HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. *Cell* (2009) 137:433–44. doi:10.1016/j.cell.2009.02.046
 36. Herold N, Anders-Osswein M, Glass B, Eckhardt M, Muller B, Krausslich HG. HIV-1 entry in SupT1-R5, CEM-ss, and primary CD4+ T cells occurs at the plasma membrane and does not require endocytosis. *J Virol* (2014) 88:13956–70. doi:10.1128/JVI.01543-14
 37. Jones DM, Alvarez LA, Nolan R, Ferriz M, Sainz Urruela R, Massana-Munoz X, et al. Dynamin-2 stabilizes the HIV-1 fusion pore with a low oligomeric state. *Cell Rep* (2017) 18:443–53. doi:10.1016/j.celrep.2016.12.032
 38. Sundquist WI, Krausslich HG. HIV-1 assembly, budding, and maturation. *Cold Spring Harb Perspect Med* (2012) 2:a006924. doi:10.1101/cshperspect.a006924
 39. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. *J Virol* (2009) 83:3719–33. doi:10.1128/JVI.01844-08
 40. Schreiber G. The molecular basis for differential type I interferon signaling. *J Biol Chem* (2017) 292:7285–94. doi:10.1074/jbc.R116.774562
 41. Neil S, Bieniasz P. Human immunodeficiency virus, restriction factors, and interferon. *J Interferon Cytokine Res* (2009) 29:569–80. doi:10.1089/jir.2009.0077
 42. Kirchhoff F. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. *Cell Host Microbe* (2010) 8:55–67. doi:10.1016/j.chom.2010.06.004
 43. Doyle T, Goujon C, Malim MH. HIV-1 and interferons: who's interfering with whom? *Nat Rev Microbiol* (2015) 13:403–13. doi:10.1038/nrmicro3449
 44. Goujon C, Malim MH. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. *J Virol* (2010) 84:9254–66. doi:10.1128/JVI.00854-10
 45. Pillai SK, Abdel-Mohsen M, Guatelli J, Skasko M, Monto A, Fujimoto K, et al. Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. *Proc Natl Acad Sci U S A* (2012) 109:3035–40. doi:10.1073/pnas.1111573109
 46. Barouch DH, Ghneim K, Bosche WJ, Li Y, Berkemeier B, Hull M, et al. Rapid inflammasome activation following mucosal SIV infection of rhesus monkeys. *Cell* (2016) 165:656–67. doi:10.1016/j.cell.2016.03.021
 47. Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. *Nature* (2014) 511:601–5. doi:10.1038/nature13554
 48. Fenton-May AE, Dibben O, Emmerich T, Ding H, Pfaffert K, Aasa-Chapman MM, et al. Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology* (2013) 10:146. doi:10.1186/1742-4690-10-146
 49. Deymier MJ, Ende Z, Fenton-May AE, Dilernia DA, Kilemba W, Allen SA, et al. Heterosexual transmission of subtype C HIV-1 selects consensus-like variants without increased replicative capacity or interferon-alpha resistance. *PLoS Pathog* (2015) 11:e1005154. doi:10.1371/journal.ppat.1005154
 50. Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG, et al. Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. *Proc Natl Acad Sci U S A* (2017) 114:E590–9. doi:10.1073/pnas.1620144114
 51. Brass AL, Huang IC, Benita Y, John SP, Krishnan MN, Feeley EM, et al. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. *Cell* (2009) 139:1243–54. doi:10.1016/j.cell.2009.12.017
 52. Huang IC, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, et al. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. *PLoS Pathog* (2011) 7:e1001258. doi:10.1371/journal.ppat.1001258
 53. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. The IFITM proteins inhibit HIV-1 infection. *J Virol* (2011) 85:2126–37. doi:10.1128/JVI.01531-10
 54. Weston S, Czieso S, White IJ, Smith SE, Kellam P, Marsh M. A membrane topology model for human interferon inducible transmembrane protein 1. *PLoS One* (2014) 9:e104341. doi:10.1371/journal.pone.0104341
 55. Bailey CC, Kondur HR, Huang IC, Farzan M. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. *J Biol Chem* (2013) 288:32184–93. doi:10.1074/jbc.M113.514356
 56. Bailey CC, Zhong G, Huang IC, Farzan M. IFITM-family proteins: the cell's first line of antiviral defense. *Annu Rev Virol* (2014) 1:261–83. doi:10.1146/annurev-virology-031413-085537
 57. Smith S, Weston S, Kellam P, Marsh M. IFITM proteins: cellular inhibitors of viral entry. *Curr Opin Virol* (2014) 4:71–7. doi:10.1016/j.coviro.2013.11.004
 58. Sallman Almen M, Bringeland N, Fredriksson R, Schioth HB. The dispanins: a novel gene family of ancient origin that contains 14 human members. *PLoS One* (2012) 7:e31961. doi:10.1371/journal.pone.0031961
 59. Ling S, Zhang C, Wang W, Cai X, Yu L, Wu F, et al. Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3. *Sci Rep* (2016) 6:24029. doi:10.1038/srep24029
 60. Hach JC, McMichael T, Chesarino NM, Yount JS. Palmitoylation on conserved and nonconserved cysteines of murine IFITM1 regulates its stability and anti-influenza A virus activity. *J Virol* (2013) 87:9923–7. doi:10.1128/JVI.00621-13
 61. Yount JS, Karssemeijer RA, Hang HC. S-palmitoylation and ubiquitination differentially regulate interferon-induced transmembrane protein 3 (IFITM3)-mediated resistance to influenza virus. *J Biol Chem* (2012) 287:19631–41. doi:10.1074/jbc.M112.362095
 62. Yount JS, Moltedo B, Yang YY, Charron G, Moran TM, Lopez CB, et al. Palmitoylation profiling reveals S-palmitoylation-dependent antiviral activity of IFITM3. *Nat Chem Biol* (2010) 6:610–4. doi:10.1038/nchembio.405
 63. John SP, Chin CR, Perreira JM, Feeley EM, Aker AM, Savidis G, et al. The CD225 domain of IFITM3 is required for both IFITM protein association and inhibition of influenza A virus and dengue virus replication. *J Virol* (2013) 87:7837–52. doi:10.1128/JVI.00481-13
 64. Zhang Z, Liu J, Li M, Yang H, Zhang C. Evolutionary dynamics of the interferon-induced transmembrane gene family in vertebrates. *PLoS One* (2012) 7:e49265. doi:10.1371/journal.pone.0049265
 65. Compton AA, Roy N, Porrot F, Billet A, Casartelli N, Yount JS, et al. Natural mutations in IFITM3 modulate post-translational regulation and toggle antiviral specificity. *EMBO Rep* (2016) 17:1657–71. doi:10.15252/embr.201642771
 66. Jia R, Pan Q, Ding S, Rong L, Liu SL, Geng Y, et al. The N-terminal region of IFITM3 modulates its antiviral activity by regulating IFITM3 cellular localization. *J Virol* (2012) 86:13697–707. doi:10.1128/JVI.01828-12
 67. Jia R, Xu F, Qian J, Yao Y, Miao C, Zheng YM, et al. Identification of an endocytic signal essential for the antiviral action of IFITM3. *Cell Microbiol* (2014) 16:1080–93. doi:10.1111/cmi.12262
 68. Chesarino NM, McMichael T, Yount JS. E3 ubiquitin ligase NEDD4 promotes influenza virus infection by decreasing levels of the antiviral protein IFITM3. *PLoS Pathog* (2015) 11:e1005095. doi:10.1371/journal.ppat.1005095
 69. Amini-Bavil-Olyaei S, Choi YJ, Lee JH, Shi M, Huang IC, Farzan M, et al. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. *Cell Host Microbe* (2013) 13:452–64. doi:10.1016/j.chom.2013.03.006

70. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. *PLoS Pathog* (2014) 10:e1004048. doi:10.1371/journal.ppat.1004048
71. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen LM, et al. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. *PLoS Pathog* (2011) 7:e1002337. doi:10.1371/journal.ppat.1002337
72. Li K, Markosyan RM, Zheng YM, Golfetto O, Bungart B, Li M, et al. IFITM proteins restrict viral membrane hemifusion. *PLoS Pathog* (2013) 9:e1003124. doi:10.1371/journal.ppat.1003124
73. Lin TY, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, et al. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. *Cell Rep* (2013) 5:895–908. doi:10.1016/j.celrep.2013.10.033
74. Anafu AA, Bowen CH, Chin CR, Brass AL, Holm GH. Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. *J Biol Chem* (2013) 288:17261–71. doi:10.1074/jbc.M112.438515
75. Weston S, Czieso S, White IJ, Smith SE, Wash RS, Diaz-Soria C, et al. Alphavirus restriction by IFITM proteins. *Traffic* (2016) 17:997–1013. doi:10.1111/tra.12416
76. Fu B, Wang L, Li S, Dorf ME. ZMPSTE24 defends against influenza and other pathogenic viruses. *J Exp Med* (2017) 214:919–29. doi:10.1084/jem.20161270
77. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, et al. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. *Cell Host Microbe* (2014) 16:736–47. doi:10.1016/j.chom.2014.11.001
78. Tartour K, Appourchaux R, Gaillard J, Nguyen XN, Durand S, Turpin J, et al. IFITM proteins are incorporated onto HIV-1 virion particles and negatively imprint their infectivity. *Retrovirology* (2014) 11:103. doi:10.1186/s12977-014-0103-y
79. Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, et al. IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. *Cell Rep* (2015) 13:145–56. doi:10.1016/j.celrep.2015.08.055
80. Foster TL, Wilson H, Iyer SS, Coss K, Doores K, Smith S, et al. Resistance of transmitted founder HIV-1 to IFITM-mediated restriction. *Cell Host Microbe* (2016) 20:429–42. doi:10.1016/j.chom.2016.08.006
81. Tartour K, Nguyen XN, Appourchaux R, Assil S, Barateau V, Bloyet LM, et al. Interference with the production of infectious viral particles and bimodal inhibition of replication are broadly conserved antiviral properties of IFITMs. *PLoS Pathog* (2017) 13:e1006610. doi:10.1371/journal.ppat.1006610
82. Wang Y, Pan Q, Ding S, Wang Z, Yu J, Finzi A, et al. The V3 loop of HIV-1 Env determines viral susceptibility to IFITM3 impairment of viral infectivity. *J Virol* (2017) 91:e2441–2416. doi:10.1128/JVI.02441-16
83. Wu WL, Grotefend CR, Tsai MT, Wang YL, Radic V, Eoh H, et al. Delta20 IFITM2 differentially restricts X4 and R5 HIV-1. *Proc Natl Acad Sci U S A* (2017) 114:7112–7. doi:10.1073/pnas.1619640114
84. Schmidtmayerova H, Alfano M, Nuovo G, Bukrinsky M. Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level. *J Virol* (1998) 72:4633–42.
85. Ding S, Pan Q, Liu SL, Liang C. HIV-1 mutates to evade IFITM1 restriction. *Virology* (2014) 454:455–11–24. doi:10.1016/j.virol.2014.01.020
86. Bar KJ, Tsao CY, Iyer SS, Decker JM, Yang Y, Bonsignori M, et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. *PLoS Pathog* (2012) 8:e1002721. doi:10.1371/journal.ppat.1002721
87. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. *Nature* (2002) 418:646–50. doi:10.1038/nature00939
88. Boyd DE, Sharma A, Humes D, Cheng-Mayer C, Overbaugh J. Adapting SHIVs in vivo selects for envelope-mediated interferon-alpha resistance. *PLoS Pathog* (2016) 12:e1005727. doi:10.1371/journal.ppat.1005727
89. Tso FY, Abrahamyan L, Hu SL, Ruprecht RM, Wood C. Variations in the biological functions of HIV-1 clade C envelope in a SHIV-infected rhesus macaque during disease progression. *PLoS One* (2013) 8:e66973. doi:10.1371/journal.pone.0066973
90. Qian J, Le Duff Y, Wang Y, Pan Q, Ding S, Zheng YM, et al. Primate lentiviruses are differentially inhibited by interferon-induced transmembrane proteins. *Virology* (2015) 474:10–8. doi:10.1016/j.virol.2014.10.015
91. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, et al. IFITM3 restricts the morbidity and mortality associated with influenza. *Nature* (2012) 484:519–23. doi:10.1038/nature10921
92. Lopez-Rodriguez M, Herrera-Ramos E, Sole-Violan J, Ruiz-Hernandez JJ, Borderias L, Horcajada JP, et al. IFITM3 and severe influenza virus infection. No evidence of genetic association. *Eur J Clin Microbiol Infect Dis* (2016) 35:1811–7. doi:10.1007/s10096-016-2732-7
93. Pan Y, Yang P, Dong T, Zhang Y, Shi W, Peng X, et al. IFITM3 Rs12252-C variant increases potential risk for severe influenza virus infection in Chinese population. *Front Cell Infect Microbiol* (2017) 7:294. doi:10.3389/fcimb.2017.00294
94. Randolph AG, Yip WK, Allen EK, Rosenberger CM, Agan AA, Ash SA, et al. Evaluation of IFITM3 rs12252 association with severe pediatric influenza infection. *J Infect Dis* (2017) 216:14–21. doi:10.1093/infdis/jix242
95. Williams DE, Wu WL, Grotefend CR, Radic V, Chung C, Chung YH, et al. IFITM3 polymorphism rs12252-C restricts influenza A viruses. *PLoS One* (2014) 9:e110096. doi:10.1371/journal.pone.0110096
96. Wu H, Makvandi-Nejad S, Qin L, Zhao Y, Zhang T, Wang L, et al. Interferon-induced transmembrane protein-3 rs12252-C is associated with rapid progression of acute HIV-1 infection in Chinese MSM cohort. *AIDS* (2015) 29(8):889–94. doi:10.1097/QAD.0000000000000632
97. Xuan Y, Wang LN, Li W, Zi HR, Guo Y, Yan WJ, et al. IFITM3 rs12252 T>C polymorphism is associated with the risk of severe influenza: a meta-analysis. *Epidemiol Infect* (2015) 143(14):2975–84. doi:10.1017/S0950268815000278
98. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. *J Virol* (2014) 88:2633–44. doi:10.1128/JVI.03230-13
99. Basmaciogullari S, Pizzato M. The activity of Nef on HIV-1 infectivity. *Front Microbiol* (2014) 5:232. doi:10.3389/fmicb.2014.00232
100. Usami Y, Gottlinger H. HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity. *Cell Rep* (2013) 5:802–12. doi:10.1016/j.celrep.2013.09.028
101. Lai RP, Yan J, Heeney J, McClure MO, Gottlinger H, Luban J, et al. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. *PLoS Pathog* (2011) 7:e1002442. doi:10.1371/journal.ppat.1002442
102. Pizzato M, Helander A, Popova E, Calistri A, Zamborlini A, Palu G, et al. Dynamin 2 is required for the enhancement of HIV-1 infectivity by Nef. *Proc Natl Acad Sci U S A* (2007) 104:6812–7. doi:10.1073/pnas.0607622104
103. Pizzato M. MLV glycosylated-Gag is an infectivity factor that rescues Nef-deficient HIV-1. *Proc Natl Acad Sci U S A* (2010) 107:9364–9. doi:10.1073/pnas.1001554107
104. Usami Y, Popov S, Gottlinger HG. The Nef-like effect of murine leukemia virus glycosylated gag on HIV-1 infectivity is mediated by its cytoplasmic domain and depends on the AP-2 adaptor complex. *J Virol* (2014) 88:3443–54. doi:10.1128/JVI.01933-13
105. Matheson NJ, Sumner J, Wals K, Rapiteanu R, Weekes MP, Vigan R, et al. Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef. *Cell Host Microbe* (2015) 18:409–23. doi:10.1016/j.chom.2015.09.003
106. Ahi YS, Zhang S, Thappeta Y, Denman A, Feizpour A, Gummuluru S, et al. Functional interplay between murine leukemia virus glycoprotein, serinc5, and surface glycoprotein governs virus entry, with opposite effects on gammaretroviral and ebolavirus glycoproteins. *MBio* (2016) 7:e1985–1916. doi:10.1128/mBio.01985-16
107. Chande A, Cuccurullo EC, Rosa A, Ziglio S, Carpenter S, Pizzato M. S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3. *Proc Natl Acad Sci U S A* (2016) 113:13197–202. doi:10.1073/pnas.1612044113
108. Murrell B, Vollbrecht T, Guatelli J, Wertheim JO. The evolutionary histories of antiretroviral proteins SERINC3 and SERINC5 do not support an evolutionary arms race in primates. *J Virol* (2016) 90:8085–9. doi:10.1128/JVI.00972-16
109. Zhang X, Zhou T, Yang J, Lin Y, Shi J, Zhang X, et al. Identification of SERINC5-001 as the predominant spliced isoform for HIV-1 restriction. *J Virol* (2017) 91:e137–117. doi:10.1128/JVI.00137-17

110. Inuzuka M, Hayakawa M, Ingi T. Serinc, an activity-regulated protein family, incorporates serine into membrane lipid synthesis. *J Biol Chem* (2005) 280:35776–83. doi:10.1074/jbc.M505712200
111. Trautz B, Pierini V, Wombacher R, Stolp B, Chase AJ, Pizzato M, et al. The antagonism of HIV-1 Nef to SERINC5 particle infectivity restriction involves the counteraction of virion-associated pools of the restriction factor. *J Virol* (2016) 90:10915–27. doi:10.1128/JVI.01246-16
112. Beitari S, Ding S, Pan Q, Finzi A, Liang C. Effect of HIV-1 Env on SERINC5 antagonism. *J Virol* (2017) 91:e2214–6. doi:10.1128/JVI.02214-16
113. Sood C, Marin M, Chande A, Pizzato M, Melikyan GB. SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. *J Biol Chem* (2017) 292:6014–26. doi:10.1074/jbc.M117.777714
114. Heigle A, Kmiec D, Regensburger K, Langer S, Peiffer L, Sturzel CM, et al. The potency of Nef-mediated SERINC5 antagonism correlates with the prevalence of primate lentiviruses in the wild. *Cell Host Microbe* (2016) 20:381–91. doi:10.1016/j.chom.2016.08.004
115. Hatzioannou T, Perez-Caballero D, Yang A, Cowan S, Bieniasz PD. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5alpha. *Proc Natl Acad Sci U S A* (2004) 101:10774–9. doi:10.1073/pnas.0402361101
116. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. *Nature* (2004) 427:848–53. doi:10.1038/nature02343
117. McKnight A, Griffiths DJ, Dittmar M, Clapham P, Thomas E. Characterization of a late entry event in the replication cycle of human immunodeficiency virus type 2. *J Virol* (2001) 75:6914–22. doi:10.1128/JVI.75.15.6914-6922.2001
118. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, et al. Lv2, a novel postentry restriction, is mediated by both capsid and envelope. *J Virol* (2004) 78:2006–16. doi:10.1128/JVI.78.4.2006-2016.2004
119. Marchant D, Neil SJ, Aubin K, Schmitz C, McKnight A. An envelope-determined, pH-independent endocytic route of viral entry determines the susceptibility of human immunodeficiency virus type 1 (HIV-1) and HIV-2 to Lv2 restriction. *J Virol* (2005) 79:9410–8. doi:10.1128/JVI.79.15.9410-9418.2005
120. Marno KM, O'Sullivan E, Jones CE, Diaz-Delfin J, Pardieu C, Sloan RD, et al. RNA-associated early-stage antiviral factor is a major component of Lv2 restriction. *J Virol* (2017) 91:e1228–1216. doi:10.1128/JVI.01228-16
121. Marno KM, Ogunkolade BW, Pade C, Oliveira NM, O'Sullivan E, McKnight A. Novel restriction factor RNA-associated early-stage anti-viral factor (REAF) inhibits human and simian immunodeficiency viruses. *Retrovirology* (2014) 11:3. doi:10.1186/1742-4690-11-3
122. Pineda MJ, Orton BR, Overbaugh J. A TRIM5alpha-independent post-entry restriction to HIV-1 infection of macaque cells that is dependent on the path of entry. *Virology* (2007) 363:310–8. doi:10.1016/j.virol.2007.02.002
123. Ribeiro CM, Sarrami-Forooshani R, Setiawan LC, Zijlstra-Willems EM, van Hamme JL, Tigchelaar W, et al. Receptor usage dictates HIV-1 restriction by human TRIM5alpha in dendritic cell subsets. *Nature* (2016) 540:448–52. doi:10.1038/nature20567
124. Rihn SJ, Foster TL, Busnadiego I, Aziz MA, Hughes J, Neil SJ, et al. The envelope gene of transmitted HIV-1 resists a late interferon gamma-induced block. *J Virol* (2017) 91:e2254–2216. doi:10.1128/JVI.02254-16
125. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature* (2008) 451:425–30. doi:10.1038/nature06553
126. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. *Cell Host Microbe* (2008) 3:245–52. doi:10.1016/j.chom.2008.03.001
127. Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. *Cell Host Microbe* (2009) 6:409–21. doi:10.1016/j.chom.2009.10.004
128. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, Johnson MC, et al. Tetherin inhibits HIV-1 release by directly tethering virions to cells. *Cell* (2009) 139:499–511. doi:10.1016/j.cell.2009.08.039
129. Venkatesh S, Bieniasz PD. Mechanism of HIV-1 virion entrapment by tetherin. *PLoS Pathog* (2013) 9:e1003483. doi:10.1371/journal.ppat.1003483
130. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. *Traffic* (2003) 4:694–709. doi:10.1034/j.1600-0854.2003.00129.x
131. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G. Clathrin-mediated endocytosis of a lipid-raft-associated protein is mediated through a dual tyrosine motif. *J Cell Sci* (2007) 120:3850–8. doi:10.1242/jcs.003343
132. Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, Renesto P, et al. Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. *Cell Host Microbe* (2010) 7:314–23. doi:10.1016/j.chom.2010.03.005
133. Schubert HL, Zhai Q, Sandrin V, Eckert DM, Garcia-Maya M, Saul L, et al. Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. *Proc Natl Acad Sci U S A* (2010) 107:17951–6. doi:10.1073/pnas.1008206107
134. Yang H, Wang J, Jia X, McNatt MW, Zang T, Pan B, et al. Structural insight into the mechanisms of enveloped virus tethering by tetherin. *Proc Natl Acad Sci U S A* (2010) 107:18428–32. doi:10.1073/pnas.1011485107
135. Fitzpatrick K, Skasko M, Deerinck TJ, Crum J, Ellisman MH, Guatelli J. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles. *PLoS Pathog* (2010) 6:e1000701. doi:10.1371/journal.ppat.1000701
136. Hammonds J, Wang JJ, Yi H, Spearman P. Immunoelectron microscopic evidence for tetherin/BST2 as the physical bridge between HIV-1 virions and the plasma membrane. *PLoS Pathog* (2010) 6:e1000749. doi:10.1371/journal.ppat.1000749
137. Neil SJ, Eastman SW, Jouvenet N, Bieniasz PD. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane. *PLoS Pathog* (2006) 2:e39. doi:10.1371/journal.ppat.0020039
138. Perez-Caballero D, Hatzioannou T, Martin-Serrano J, Bieniasz PD. Human immunodeficiency virus type 1 matrix inhibits and confers cooperativity on gag precursor-membrane interactions. *J Virol* (2004) 78:9560–3. doi:10.1128/JVI.78.17.9560-9563.2004
139. Cocka LJ, Bates P. Identification of alternatively translated tetherin isoforms with differing antiviral and signaling activities. *PLoS Pathog* (2012) 8:e1002931. doi:10.1371/journal.ppat.1002931
140. Weinelt J, Neil SJ. Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses. *J Virol* (2014) 88:5845–58. doi:10.1128/JVI.03818-13
141. Bego MG, Mercier J, Cohen EA. Virus-activated interferon regulatory factor 7 upregulates expression of the interferon-regulated BST2 gene independently of interferon signaling. *J Virol* (2012) 86:3513–27. doi:10.1128/JVI.06971-11
142. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, Colonna M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. *J Immunol* (2006) 177:3260–5. doi:10.4049/jimmunol.177.5.3260
143. Homann S, Smith D, Little S, Richman D, Guatelli J. Upregulation of BST-2/tetherin by HIV infection in vivo. *J Virol* (2011) 85:10659–68. doi:10.1128/JVI.05524-11
144. Erikson E, Adam T, Schmidt S, Lehmann-Koch J, Over B, Goffinet C, et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. *Proc Natl Acad Sci U S A* (2011) 108:13688–93. doi:10.1073/pnas.1101684108
145. Sharp PM, Hahn BH. Origins of HIV and the AIDS Pandemic. *Cold Spring Harb Perspect Med* (2011) 1:a006841. doi:10.1101/cshperspect.a006841
146. Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SE, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. *Nature* (1999) 397:436–41. doi:10.1038/17130
147. Keele BF, Van Heuverswyn F, Li Y, Bailes E, Takehisa J, Santiago ML, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. *Science* (2006) 313:523–6. doi:10.1126/science.1126531
148. D'Arc M, Ayoub A, Esteban A, Learn GH, Boue V, Liegeois F, et al. Origin of the HIV-1 group O epidemic in western lowland gorillas. *Proc Natl Acad Sci U S A* (2015) 112:E1343–52. doi:10.1073/pnas.1502022112
149. Van Heuverswyn F, Li Y, Neel C, Bailes E, Keele BF, Liu W, et al. Human immunodeficiency viruses: SIV infection in wild gorillas. *Nature* (2006) 444:164. doi:10.1038/444164a
150. Chen Z, Telfer P, Gettie A, Reed P, Zhang L, Ho DD, et al. Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human

- immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop. *J Virol* (1996) 70:3617–27.
151. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, et al. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. *Nature* (1992) 358:495–9. doi:10.1038/358495a0
 152. Hirsch VM, Olmsted RA, Murphey-Corb M, Purcell RH, Johnson PR. An African primate lentivirus (SIVsm) closely related to HIV-2. *Nature* (1989) 339:389–92. doi:10.1038/339389a0
 153. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, et al. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. *PLoS Pathog* (2009) 5:e1000429. doi:10.1371/journal.ppat.1000429
 154. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, et al. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. *Cell Host Microbe* (2009) 6:54–67. doi:10.1016/j.chom.2009.05.008
 155. Sauter D, Kirchhoff F. Tetherin antagonism by primate lentiviral Nef proteins. *Curr HIV Res* (2011) 9:514–23. doi:10.2174/157016211798842044
 156. Sauter D, Vogl M, Kirchhoff F. Ancient origin of a deletion in human BST2/tetherin that confers protection against viral zoonoses. *Hum Mutat* (2011) 32:1243–5. doi:10.1002/humu.21571
 157. Dube M, Paquay C, Roy BB, Bego MG, Mercier J, Cohen EA. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. *Traffic* (2011) 12:1714–29. doi:10.1111/j.1600-0854.2011.01277.x
 158. McNatt MW, Zang T, Bieniasz PD. Vpu binds directly to tetherin and displaces it from nascent virions. *PLoS Pathog* (2013) 9:e1003299. doi:10.1371/journal.ppat.1003299
 159. Skasko M, Wang Y, Tian Y, Tokarev A, Munguia J, Ruiz A, et al. HIV-1 Vpu protein antagonizes innate restriction factor BST-2 via lipid-embedded helix-helix interactions. *J Biol Chem* (2012) 287:58–67. doi:10.1074/jbc.M111.296772
 160. Vigan R, Neil SJ. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein. *J Virol* (2010) 84:12958–70. doi:10.1128/JVI.01699-10
 161. Kluge SE, Sauter D, Vogl M, Peeters M, Li Y, Bibollet-Ruche F, et al. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function. *Retrovirology* (2013) 10:32. doi:10.1186/1742-4690-10-32
 162. Mitchell RS, Katsura C, Skasko MA, Fitzpatrick K, Lau D, Ruiz A, et al. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking. *PLoS Pathog* (2009) 5:e1000450. doi:10.1371/journal.ppat.1000450
 163. Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, et al. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. *Elife* (2014) 3:e02362. doi:10.7554/eLife.02362
 164. Kueck T, Foster TL, Weinelt J, Sumner JC, Pickering S, Neil SJ. Serine phosphorylation of HIV-1 Vpu and its binding to tetherin regulates interaction with clathrin adaptors. *PLoS Pathog* (2015) 11:e1005141. doi:10.1371/journal.ppat.1005141
 165. Stoneham CA, Singh R, Jia X, Xiong Y, Guatelli J. Endocytic activity of HIV-1 Vpu: phosphoserine-dependent interactions with clathrin adaptors. *Traffic* (2017) 18:545–61. doi:10.1111/tra.12495
 166. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, Piguet V. HIV-1 Vpu neutralizes the antiviral factor tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation. *PLoS Pathog* (2009) 5:e1000574. doi:10.1371/journal.ppat.1000574
 167. Margottin F, Bour SP, Durand H, Selig L, Benichou S, Richard V, et al. A novel human WD protein, h-beta TrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. *Mol Cell* (1998) 1:565–74. doi:10.1016/S1097-2765(00)80056-8
 168. Schmidt S, Fritz JV, Bitzegeio J, Fackler OT, Keppler OT. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. *MBio* (2011) 2:e00036–11. doi:10.1128/mBio.00036-11
 169. Tervo HM, Homann S, Ambiel I, Fritz JV, Fackler OT, Keppler OT. beta-TrCP is dispensable for Vpu's ability to overcome the CD317/tetherin-imposed restriction to HIV-1 release. *Retrovirology* (2011) 8:9. doi:10.1186/1742-4690-8-9
 170. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, Moses AV. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism. *J Virol* (2009) 83:7931–47. doi:10.1128/JVI.00242-09
 171. Gustin JK, Douglas JL, Bai Y, Moses AV. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain. *J Biol Chem* (2012) 287:14837–50. doi:10.1074/jbc.M112.349928
 172. Tokarev AA, Munguia J, Guatelli JC. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. *J Virol* (2011) 85:51–63. doi:10.1128/JVI.01795-10
 173. Agromayor M, Soler N, Caballe A, Kueck T, Freund SM, Allen MD, et al. The UBAP1 subunit of ESCRT-I interacts with ubiquitin via a SOUBA domain. *Structure* (2012) 20:414–28. doi:10.1016/j.str.2011.12.013
 174. Janvier K, Pelchen-Matthews A, Renaud JB, Caillet M, Marsh M, Berlioz-Torrent C. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation. *PLoS Pathog* (2011) 7:e1001265. doi:10.1371/journal.ppat.1001265
 175. Kueck T, Neil SJ. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction. *PLoS Pathog* (2012) 8:e1002609. doi:10.1371/journal.ppat.1002609
 176. Jafari M, Guatelli J, Lewinski MK. Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. *J Virol* (2014) 88:5062–78. doi:10.1128/JVI.03472-13
 177. Pickering S, Hue S, Kim EY, Reddy S, Wolinsky SM, Neil SJ. Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals. *PLoS Pathog* (2014) 10:e1003895. doi:10.1371/journal.ppat.1003895
 178. Sauter D, Hotter D, Van Driessche B, Sturzel CM, Kluge SE, Wildum S, et al. Differential regulation of NF-kappaB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. *Cell Rep* (2015) 10:586–99. doi:10.1016/j.celrep.2014.12.047
 179. Kmiec D, Iyer SS, Sturzel CM, Sauter D, Hahn BH, Kirchhoff F. Vpu-mediated counteraction of tetherin is a major determinant of HIV-1 interferon resistance. *MBio* (2016) 7:e934–916. doi:10.1128/mBio.00934-16
 180. Arias JF, Colomer-Lluch M, von Bredow B, Greene JM, MacDonald J, O'Connor DH, et al. Tetherin antagonism by HIV-1 group M Nef proteins. *J Virol* (2016) 90(23):10701–14. doi:10.1128/JVI.01465-16
 181. Sauter D, Unterwiesing D, Vogl M, Usmami SM, Heigle A, Kluge SE, et al. Human tetherin exerts strong selection pressure on the HIV-1 group N Vpu protein. *PLoS Pathog* (2012) 8:e1003093. doi:10.1371/journal.ppat.1003093
 182. Vigan R, Neil SJ. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin. *J Virol* (2011) 85:9737–48. doi:10.1128/JVI.00479-11
 183. Yang SJ, Lopez LA, Exline CM, Haworth KG, Cannon PM. Lack of adaptation to human tetherin in HIV-1 group O and P. *Retrovirology* (2011) 8:78. doi:10.1186/1742-4690-8-78
 184. Kluge SE, Mack K, Iyer SS, Pujol FM, Heigle A, Learn GH, et al. Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. *Cell Host Microbe* (2014) 16:639–50. doi:10.1016/j.chom.2014.10.002
 185. Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, et al. Efficient Vpu-mediated tetherin antagonism by an HIV-1 group O strain. *J Virol* (2017) 91:e2177–2116. doi:10.1128/JVI.02177-16
 186. Plantier JC, Leoz M, Dickerson JE, De Oliveira F, Cordonnier F, Lemee V, et al. A new human immunodeficiency virus derived from gorillas. *Nat Med* (2009) 15:871–2. doi:10.1038/nm.2016
 187. Vallari A, Holzmayer V, Harris B, Yamaguchi J, Ngansop C, Makamche F, et al. Confirmation of putative HIV-1 group P in Cameroon. *J Virol* (2011) 85:1403–7. doi:10.1128/JVI.02005-10
 188. Sauter D, Hue S, Petit SJ, Plantier JC, Towers GJ, Kirchhoff F, et al. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef. *Retrovirology* (2011) 8:103. doi:10.1186/1742-4690-8-103

189. Serra-Moreno R, Zimmermann K, Stern LJ, Evans DT. Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. *PLoS Pathog* (2013) 9:e1003487. doi:10.1371/journal.ppat.1003487
190. Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, Hatzioannou T. SIV Nef proteins recruit the AP-2 complex to antagonize tetherin and facilitate virion release. *PLoS Pathog* (2011) 7:e1002039. doi:10.1371/journal.ppat.1002039
191. Le Tortorec A, Neil SJ. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. *J Virol* (2009) 83:11966–78. doi:10.1128/JVI.01515-09
192. Abada P, Noble B, Cannon PM. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. *J Virol* (2005) 79:3627–38. doi:10.1128/JVI.79.6.3627-3638.2005
193. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, Guatelli JC, et al. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. *Retrovirology* (2010) 7:51. doi:10.1186/1742-4690-7-51
194. Noble B, Abada P, Nunez-Iglesias J, Cannon PM. Recruitment of the adaptor protein 2 complex by the human immunodeficiency virus type 2 envelope protein is necessary for high levels of virus release. *J Virol* (2006) 80:2924–32. doi:10.1128/JVI.80.6.2924-2932.2006
195. Chen CY, Shingai M, Welbourn S, Martin MA, Borrego P, Taveira N, et al. Antagonism of BST-2/tetherin is a conserved function of the Env glycoprotein of primary HIV-2 isolates. *J Virol* (2016) 90:11062–74. doi:10.1128/JVI.01451-16
196. Gotz N, Sauter D, Usmani SM, Fritz JV, Goffinet C, Heigle A, et al. Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. *Cell Host Microbe* (2012) 12:373–80. doi:10.1016/j.chom.2012.07.008
197. Hatzioannou T, Del Prete GQ, Keele BF, Estes JD, McNatt MW, Bitzegeio J, et al. HIV-1-induced AIDS in monkeys. *Science* (2014) 344:1401–5. doi:10.1126/science.1250761
198. Alexander L, Ilyinskii PO, Lang SM, Means RE, Lifson J, Mansfield K, et al. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with Nef deleted in rhesus monkeys. *J Virol* (2003) 77:6823–35. doi:10.1128/JVI.77.12.6823-6835.2003
199. Serra-Moreno R, Jia B, Breed M, Alvarez X, Evans DT. Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic Nef-deleted SIV. *Cell Host Microbe* (2011) 9:46–57. doi:10.1016/j.chom.2010.12.005
200. Gupta RK, Mlcochova P, Pelchen-Matthews A, Petit SJ, Mattiuzzo G, Pillay D, et al. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. *Proc Natl Acad Sci U S A* (2009) 106:20889–94. doi:10.1073/pnas.0907075106
201. Matsuda K, Chen CY, Whitted S, Chertova E, Roser DJ, Wu F, et al. Enhanced antagonism of BST-2 by a neurovirulent SIV envelope. *J Clin Invest* (2016) 126:2295–307. doi:10.1172/JCI83725
202. Liberatore RA, Bieniasz PD. Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. *Proc Natl Acad Sci U S A* (2011) 108:18097–101. doi:10.1073/pnas.1113694108
203. Blanco-Melo D, Venkatesh S, Bieniasz PD. Origins and evolution of tetherin, an orphan antiviral gene. *Cell Host Microbe* (2016) 20:189–201. doi:10.1016/j.chom.2016.06.007
204. Heusinger E, Kluge SF, Kirchhoff F, Sauter D. Early vertebrate evolution of the host restriction factor tetherin. *J Virol* (2015) 89:12154–65. doi:10.1128/JVI.02149-15
205. Jolly C. T cell polarization at the virological synapse. *Viruses* (2010) 2:1261–78. doi:10.3390/v2061261
206. Jolly C, Booth NJ, Neil SJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. *J Virol* (2010) 84:12185–99. doi:10.1128/JVI.01447-10
207. Alvarez RA, Hamlin RE, Monroe A, Moldt B, Hotta MT, Rodriguez Caprio G, et al. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. *J Virol* (2014) 88:6031–46. doi:10.1128/JVI.00449-14
208. Arias JF, Heyer LN, von Bredow B, Weisgrau KL, Moldt B, Burton DR, et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. *Proc Natl Acad Sci U S A* (2014) 111:6425–30. doi:10.1073/pnas.1321507111
209. Pham TN, Lukhele S, Hajjar F, Routy JP, Cohen EA. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. *Retrovirology* (2014) 11:15. doi:10.1186/1742-4690-11-15
210. Galao RP, Le Tortorec A, Pickering S, Kueck T, Neil SJ. Innate sensing of HIV-1 assembly by tetherin induces NF-kappaB-dependent proinflammatory responses. *Cell Host Microbe* (2012) 12:633–44. doi:10.1016/j.chom.2012.10.007
211. Tokarev A, Suarez M, Kwan W, Fitzpatrick K, Singh R, Guatelli J. Stimulation of NF-kappaB activity by the HIV restriction factor BST2. *J Virol* (2013) 87:2046–57. doi:10.1128/JVI.02272-12
212. Galao RP, Pickering S, Curnock R, Neil SJ. Retroviral retention activates a Syk-dependent HemITAM in human tetherin. *Cell Host Microbe* (2014) 16:291–303. doi:10.1016/j.chom.2014.08.005
213. Rollason R, Korolchuk V, Hamilton C, Jepson M, Banting G. A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. *J Cell Biol* (2009) 184:721–36. doi:10.1083/jcb.200804154
214. Liberatore RA, Mastrocola EJ, Powell C, Bieniasz PD. Tetherin inhibits cell-free virus dissemination and retards murine leukemia virus pathogenesis. *J Virol* (2017) 91(12):e02286-16. doi:10.1128/JVI.02286-16
215. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, Bao M, et al. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. *J Exp Med* (2009) 206:1603–14. doi:10.1084/jem.20090547
216. Bego MG, Cote E, Aschman N, Mercier J, Weissenhorn W, Cohen EA. Vpu exploits the cross-talk between BST2 and the ILT7 receptor to suppress anti-HIV-1 responses by plasmacytoid dendritic cells. *PLoS Pathog* (2015) 11:e1005024. doi:10.1371/journal.ppat.1005024
217. Bego MG, Cong L, Mack K, Kirchhoff F, Cohen EA. Differential control of BST2 restriction and plasmacytoid dendritic cell antiviral response by antagonists encoded by HIV-1 group M and O strains. *J Virol* (2016) 90:10236–46. doi:10.1128/JVI.01131-16
218. Lama J, Mangasarian A, Trono D. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. *Curr Biol* (1999) 9:622–31. doi:10.1016/S0960-9822(99)80284-X
219. Amara A, Mercer J. Viral apoptotic mimicry. *Nat Rev Microbiol* (2015) 13:461–9. doi:10.1038/nrmicro3469
220. Li M, Ablan SD, Miao C, Zheng YM, Fuller MS, Rennert PD, et al. TIM-family proteins inhibit HIV-1 release. *Proc Natl Acad Sci U S A* (2014) 111:E3699–707. doi:10.1073/pnas.1404851111
221. Kim HY, Eyheramonho MB, Pichavant M, Gonzalez Cambaceres C, Matangkasombut P, Cervio G, et al. A polymorphism in TIM1 is associated with susceptibility to severe hepatitis A virus infection in humans. *J Clin Invest* (2011) 121:1111–8. doi:10.1172/JCI44182
222. Biasin M, Sironi M, Saulle I, Pontremoli C, Garziano M, Cagliani R, et al. A 6-amino acid insertion/deletion polymorphism in the mucin domain of TIM-1 confers protections against HIV-1 infection. *Microbes Infect* (2017) 19:69–74. doi:10.1016/j.micinf.2016.09.005
223. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D, et al. Loss of infectivity by progeny virus from alpha interferon-treated human immunodeficiency virus type 1-infected T cells is associated with defective assembly of envelope gp120. *J Virol* (1992) 66:7543–8.
224. Krapp C, Hotter D, Gawanbacht A, McLaren PJ, Kluge SF, Sturzel CM, et al. Guanylate binding protein (GBP) 5 is an interferon-inducible inhibitor of HIV-1 infectivity. *Cell Host Microbe* (2016) 19:504–14. doi:10.1016/j.chom.2016.02.019
225. Lodermeier V, Suhr K, Schrott N, Kolbe C, Sturzel CM, Krnavek D, et al. 90K, an interferon-stimulated gene product, reduces the infectivity of HIV-1. *Retrovirology* (2013) 10:111. doi:10.1186/1742-4690-10-111
226. Wilson SJ, Schoggins JW, Zang T, Kutluay SB, Jouvnet N, Alim MA, et al. Inhibition of HIV-1 particle assembly by 2',3'-cyclic-nucleotide 3'-phosphodiesterase. *Cell Host Microbe* (2012) 12:585–97. doi:10.1016/j.chom.2012.08.012

227. Villarroya-Beltri C, Guerra S, Sanchez-Madrid F. ISGylation – a key to lock the cell gates for preventing the spread of threats. *J Cell Sci* (2017) 130:2961–9. doi:10.1242/jcs.205468
228. Kuang Z, Seo EJ, Leis J. Mechanism of inhibition of retrovirus release from cells by interferon-induced gene ISG15. *J Virol* (2011) 85:7153–61. doi:10.1128/JVI.02610-10
229. Pincetic A, Kuang Z, Seo EJ, Leis J. The interferon-induced gene ISG15 blocks retrovirus release from cells late in the budding process. *J Virol* (2010) 84:4725–36. doi:10.1128/JVI.02478-09
230. Martinelli N, Hartlieb B, Usami Y, Sabin C, Dordor A, Miguet N, et al. CC2D1A is a regulator of ESCRT-III CHMP4B. *J Mol Biol* (2012) 419:75–88. doi:10.1016/j.jmb.2012.02.044
231. Usami Y, Popov S, Weiss ER, Vriesema-Magnuson C, Calistri A, Gottlinger HG. Regulation of CHMP4/ESCRT-III function in human immunodeficiency virus type 1 budding by CC2D1A. *J Virol* (2012) 86:3746–56. doi:10.1128/JVI.06539-11
232. Chen KR, Chang CH, Huang CY, Lin CY, Lin WY, Lo YC, et al. TBK1-associated protein in endolysosomes (TAPE)/CC2D1A is a key regulator linking RIG-I-like receptors to antiviral immunity. *J Biol Chem* (2012) 287:32216–21. doi:10.1074/jbc.C112.394346

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Foster, Pickering and Neil. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.